Relief Therapeutics Holding (RLFTF) 20-F 30 Apr 24 2023 FY Annual report (foreign) Financial data

Cover Page

Cover Page	12 Months Ended
	Dec. 31, 2023 shares
Document Information [Line Items]
Document Type	20-F
Amendment Flag	false
Document Registration Statement	false
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	011-41174
Entity Registrant Name	RELIEF THERAPEUTICS HOLDING SA
Entity Central Index Key	0001854078
Entity Incorporation, State or Country Code	V8
Entity Address, Address Line One	Avenue de Sécheron 15
Entity Address, Postal Zip Code	1202
Entity Address, City or Town	Geneva
Entity Address, Country	CH
Entity Common Stock, Shares Outstanding	12,540,439
Title of 12(g) Security	Ordinary Stock, CHF 0.10 nominal value per share
No Trading Symbol Flag	true
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
ICFR Auditor Attestation Flag	false
Document Accounting Standard	International Financial Reporting Standards
Entity Shell Company	false
Auditor Name	MAZARS SA
Auditor Firm ID	6868
Auditor Location	Switzerland, Geneva
Document Financial Statement Error Correction [Flag]	false
Business Contact [Member]
Document Information [Line Items]
Contact Personnel Name	Michelle Lock
Entity Address, Address Line One	Avenue de Sécheron 15
Entity Address, Postal Zip Code	1202
Entity Address, City or Town	Geneva
Entity Address, Country	CH
City Area Code	41
Local Phone Number	22 545 11 16
American Depositary Shares, representing 200 shares of Ordinary Stock, par value CHF 0.01 per share [Member]
Document Information [Line Items]
Title of 12(g) Security	American Depositary Shares (each representing one share of ordinary share, CHF 0.10 nominal value per share)
No Trading Symbol Flag	true

Consolidated Balance Sheet

Consolidated Balance Sheet - CHF (SFr) SFr in Thousands	Dec. 31, 2023	Dec. 31, 2022
ASSETS
Intangible assets	SFr 54,414	SFr 162,915
Right-of-use assets	2,570	2,642
Property and equipment	397	49
Other non-current assets	116	114
Deferred tax assets	589	495
Non-current assets	58,086	166,215
Inventories	557	227
Trade receivables	1,171	1,321
Other current assets	2,020	1,798
Cash and cash equivalents	14,556	19,237
Current assets	18,304	22,583
Total assets	76,390	188,798
EQUITY AND LIABILITIES
Share capital	56,163	56,163
Reserves	220,330	220,961
Treasury shares	(6,001)	(12,108)
Accumulated losses	(218,264)	(119,599)
Equity	52,228	145,417
Non-current lease liabilities	2,086	2,232
Non-current borrowings	9	16
Defined benefit obligations	1,589	1,772
Provisions	6,203	7,909
Deferred tax liabilities	7,366	20,736
Non-current liabilities	17,253	32,665
Current lease liabilities	524	444
Current borrowings	337	372
Trade payables	1,025	1,625
Financial liabilities due to related parties	1,355	1,280
Provisions	235	3,094
Other current payables and liabilities	3,433	3,901
Current liabilities	6,909	10,716
Total equity and liabilities	SFr 76,390	SFr 188,798

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Loss - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Profit or loss [abstract]
Revenue	SFr 6,033	SFr 6,081
Other gains	295	1,029
Total income	6,328	7,110
Raw materials and consumables expenses	(1,736)	(1,250)
External selling and distribution expenses	(2,200)	(3,307)
External research and development expenses	(1,328)	(12,393)
Personnel expenses	(11,838)	(12,998)
Other administrative expenses	(5,391)	(7,747)
Other losses	(48)	(63)
EBITDA	(16,213)	(30,648)
Change in fair value of contingent consideration	4,782	8,892
Impairment expense	(96,079)	(26,424)
Amortization and depreciation expense	(3,318)	(3,860)
Operating result	(110,828)	(52,040)
Financial income	93	18
Financial expense	(949)	(2,294)
Net loss before taxes	(111,684)	(54,316)
Income taxes	13,503	3,526
Net loss for the period	(98,181)	(50,790)
OTHER COMPREHENSIVE INCOME
Remeasurement of defined benefit obligations	(484)	942
Items that will not be reclassified to profit or loss	(484)	942
Currency translation differences	63	461
Items that may be reclassified to profit or loss	63	461
Other comprehensive income for the period, net of tax	(421)	1,403
Total comprehensive loss for the period	SFr (98,602)	SFr (49,387)
EARNINGS PER SHARE
Basic loss per share (in CHF)	SFr (8.354)	SFr (4.805)
Diluted loss per share (in CHF)	SFr (8.354)	SFr (4.805)

Consolidated Statement of Cash

Consolidated Statement of Cash Flow - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Statement of cash flows [abstract]
Net loss for the period	SFr (98,181)	SFr (50,790)
Adjustments for:
Income tax (income)/expense	(13,503)	(3,526)
Depreciation and amortization expense	3,318	3,860
Impairment of intangible assets	95,895	26,424
Impairment of receivables	36	24
Reversal of impairment loss	(73)	(453)
Gain from fair value adjustments to contingent payments	(4,782)	(8,892)
Finance expenses	883	1,920
Finance income	(93)	(18)
Interest expenses paid on borrowings and lease liabilities	(143)	(374)
Gain on divestment of intangible assets	(125)
Change in defined benefit obligations	(667)	(79)
Share-based payment expense	814	2,186
Changes in working capital:
Decrease/(Increase) in inventories	(330)	164
Decrease/(Increase) in trade receivables	129	(19)
Decrease/(Increase) in other assets	(163)	6,481
(Decrease)/increase in trade payables	(599)	(75)
(Decrease)/increase in provisions	440	(586)
(Decrease)/increase in other payables and liabilities	(468)	(373)
Cash flow used in operating activities	(17,612)	(24,126)
Payments for property, plant and equipment	(446)	(33)
Payments for intangible assets		(488)
Payments for other financial assets	(5)	(38)
Proceeds from partial divestment of intangible assets	8,865
Proceeds from acquisition price adjustment of intangible assets	188
Milestone payments related to acquisition of subsidiaries		(7,920)
Proceeds from other financial assets		462
Interest received	93	18
Cash flow from (used in) investing activities	8,695	(7,999)
Proceeds from capital increase	5,014	60
Sale of treasury shares	80	7,051
Equity transaction costs	(494)	(223)
Repayment of lease liabilities	(530)	(390)
Repayment of borrowings	(20)	(81)
Cash flow from financing activities	4,050	6,417
Net increase in cash and cash equivalents	(4,867)	(25,708)
Cash and cash equivalents at beginning of period	19,237	44,761
Exchange difference on cash and cash equivalents	186	184
Cash and cash equivalents at end of period	SFr 14,556	SFr 19,237

Consolidated Statement of Chang

Consolidated Statement of Changes in Equity - CHF (SFr) SFr in Thousands	Total	Share capital [member]	Treasury shares [member]	Reserves [member]	Accumulated loss [member]
Beginning balance at Dec. 31, 2021	SFr 181,530	SFr 44,133	SFr (2,999)	SFr 210,147	SFr (69,751)
Result for the period	(50,790)				(50,790)
Other comprehensive income for the period	1,403			461	942
Total comprehensive loss for the period	(49,387)			461	(49,848)
Issuance of treasury shares		12,000	(12,000)
Direct Share Placement program	7,051		1,389	5,662
Acquisition milestone share payments	4,200		1,502	2,698
Transaction cost in relation to capital increases	(223)			(223)
Exercise of options	60	30		30
Share-based compensation cost	2,186			2,186
Ending balance at Dec. 31, 2022	145,417	56,163	(12,108)	220,961	(119,599)
Result for the period	(98,181)				(98,181)
Other comprehensive income for the period	(421)			63	(484)
Total comprehensive loss for the period	(98,602)			63	(98,665)
Direct Share Placement program	102		100	2
Private placement	4,994		4,800	194
Withdrawal of fractional shares	(22)		(12)	(10)
Transaction cost in relation to capital increases	(494)			(494)
Exercise of options	19		19
Exercise of pre-funded warrants			1,200	(1,200)
Share-based compensation cost	814			814
Ending balance at Dec. 31, 2023	SFr 52,228	SFr 56,163	SFr (6,001)	SFr 220,330	SFr (218,264)

General information

General information	12 Months Ended
	Dec. 31, 2023
Disclosure Of General Information About Financial Statements [Abstract]
General information	1. General information RELIEF THERAPEUTICS Holding SA (“Relief”, the “Company” or the “Group”) is a Swiss stock corporation domiciled at 15 Avenue de Sécheron, 1202 Geneva, Switzerland. The Company’s shares are listed on the SIX Swiss Exchange (ticker: RLF) and quoted in the U.S. on OTCQB (tickers: RLFTF, RLFTY). The Group focuses on the identification, development and commercialization of novel, patent protected products intended for the treatment of metabolic, dermatological and pulmonary rare diseases with a portfolio of clinical and marketed products that serve unmet patient needs. In March 2021, Relief signed a collaboration and license agreement with Acer Therapeutics, Inc. (“Acer”) for the worldwide development and commercialization of ACER-001 ® In June 2021, the Group acquired APR Applied Pharma Research SA (“APR”), a privately held Swiss pharmaceutical company specialized in formulating, developing, and commercializing known molecules designed with proprietary drug delivery systems for niche and specialty diseases. The acquisition transformed Relief into a fully integrated commercial-stage biopharmaceutical group. The acquisition further diversified Relief’s pipeline and portfolio with both commercial products and clinical-stage programs, provided a commercial infrastructure in Europe and strengthened internal research and development capabilities. In July 2021, the Group acquired AdVita Lifescience GmbH (“AdVita”). The acquisition strengthened the Group’s expertise and intellectual property rights around the inhaled formulation and delivery of Aviptadil. In 2022, Relief established a commercial unit in the U.S. to launch PKU GOLIKE in October 2022 and market potential future products in the U.S. market. In December 2023, the Group initiated a progressive transition from a direct marketing and sales infrastructure to a partnership-based model for its commercial-stage assets. These consolidated financial statements were approved for publication by the Board of Directors on April 29, 2024.

New and revised International F

New and revised International Financial Reporting Standards (IFRS)	12 Months Ended
	Dec. 31, 2023
Disclosure of initial application of standards or interpretations [abstract]
New and revised International Financial Reporting Standards (IFRS)	2. New and revised International Financial Reporting Standards (IFRS) 2.1 New and revised IFRS Standards and Interpretations In the current year, the Group has applied the following new or amended Standards that became effective from January 1, 2023. The revised Standards did not have a material effect on these financial statements. • Amendments to IAS 1’Presentation of Financial Statements’ on disclosure of accounting policies; • Amendments to IAS 8 ‘Accounting Policies, Changes in Accounting Estimates and Errors’ on the definition of accounting estimates; and • Amendments to IAS 12 ‘Income taxes’ on deferred tax related to assets and liabilities arising from a single transaction and on international tax reform (Pillar Two Model Rules). 2.2 IFRS Standards and Interpretations issued and not yet adopted Certain new Standards and Interpretations have been issued that are not mandatory for the current reporting period and have not been early adopted by the Group. These standards are not expected to have a material impact on the Group’s overall results and financial position. Effective and applied from January 1, 2024 • Amendments to IAS 1 ‘Presentation of financial statements’ on classification of liabilities as current or non-current non-current • Amendment to IAS 7 and IFRS 7 on disclosure of Supplier Finance Arrangements; • Amendment to IFRS 16 ‘Leases’ on lease liability in a sale-and-leaseback; Effective and applied from January 1, 2025 • Amendment to IAS 21 ‘The effects of changes in foreign exchange rates’ on lack of exchangeability.

Summary of material accounting

Summary of material accounting policies	12 Months Ended
	Dec. 31, 2023
Disclosure Of Material Accounting Policies [Abstract]
Summary of material accounting policies	3. Summary of material accounting policies 3.1 Basis of preparation The consolidated financial statements of the Group have been prepared in accordance with the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB) and comply with Swiss law. They have been prepared under the historical cost convention, as modified by the revaluation of financial instruments at fair value, and are presented in Swiss francs (CHF). All values are rounded to the nearest thousand (TCHF), except when otherwise indicated. 3.2 Reclassification A gain of TCHF 8,892 on fair value remeasurement of contingent consideration in the comparative period of the consolidated statement of comprehensive loss has been reclassified from ‘Other gains’ to a distinct line ‘Change in fair value of contingent consideration’ to conform with the current period presentation. This line item has been classified below EBITDA to enhance the presentation and understandability of the Company’s consolidated statement of comprehensive loss. Gains or losses from changes in the fair value of contingent considerations (note 18) are non-cash This reclassification had no impact on the Group’s previously reported financial positions or net loss for the period. 3.3 Basis of consolidation The consolidated financial statements comprise the financial statements of the parent company RELIEF THERAPEUTICS Holding SA and its subsidiaries as of December 31, 2023 and 2022. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Specifically, the Group controls an investee if and only if the Group has: • power over the investee (i.e., existing rights that give it the current ability to direct the relevant activities of the investee); • exposure, or rights, to variable returns from its involvement with the investee; and • the ability to use its power over the investee to affect its returns. When the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including: • any contractual arrangement with the other vote holders of the investee; • rights arising from other contractual arrangements; and • the Group’s voting rights and potential voting rights. The Group reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the year are included in the statement of comprehensive income from the date the Group gains control until the date the Group ceases to control the subsidiary. 3.4 Current versus non-current The Group presents assets and liabilities in its statement of financial position based on current/non-current • expected to be realized or intended to be sold or consumed in a normal operating cycle, which is twelve months; • held primarily for the purpose of trading; • expected to be realized within twelve months after the reporting period; or • cash or cash equivalents unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. All other assets are classified as non-current. A liability is current when: • it is expected to be settled in a normal operating cycle, which is twelve months; • it is held primarily for the purpose of trading; • it is due to be settled within twelve months after the reporting period; or • there is no unconditional right to defer the settlement of the liability within twelve months after the reporting period. The Group classifies all other liabilities as non-current. Deferred tax assets and liabilities are classified as non-current 3.5 Business combinations and goodwill Business combinations are accounted for using the acquisition method. The cost of an acquisition is measured as the aggregate of the consideration transferred measured at acquisition date fair value and the amount of any non-controlling non-controlling When the Group acquires a business, it assesses the financial assets and liabilities assumed for appropriate classification and designation in accordance with the contractual terms, economic circumstances and pertinent conditions as of the acquisition date. This includes the separation of embedded derivatives in host contracts by the acquiree. If the business combination is achieved in stages, any previously held equity interest is re-measured Any contingent consideration to be transferred by the acquirer will be recognized at fair value at the acquisition date. Contingent consideration classified as an asset or liability that is a financial instrument and within the scope of IFRS 9, is measured at fair value with changes in fair value recognized in profit or loss. If the contingent consideration is not within the scope of IFRS 9, it is measured in accordance with the applicable IFRS. Contingent consideration that is classified as equity, if any, is not re-measured Goodwill is initially measured at cost, being the excess of the aggregate of the consideration transferred and the amount recognized for non-controlling re-assesses After initial recognition, goodwill is measured at cost less any accumulated impairment losses. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to the Group’s cash-generating units that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units. Where goodwill has been allocated to a cash-generating unit and part of the operation within that unit is disposed of, the goodwill associated with the disposed operation is included in the carrying amount of the operation when determining the gain or loss on disposal. Goodwill disposed in these circumstances is measured based on the relative values of the disposed operation and the portion of the cash-generating unit retained. 3.6 Revenue recognition Relief may generate revenues from collaboration and license agreements under which Relief grants licenses to use, research, develop, manufacture and commercialize product candidates and products. Relief determined that those collaboration and license agreements qualify as contracts with its customers. If the grant of a license is bundled together with the rendering of services, it is assessed whether these agreements are comprised of more than one performance obligation. A performance obligation is only accounted for as the grant of a license if the grant of a license is the sole or the predominant promise of the performance obligation. If the consideration in an agreement includes a variable amount, Relief estimates the amount of consideration to which Relief will be entitled in exchange for transferring the goods to the customer. At contract inception, the variable consideration is estimated based on the most likely amount of consideration expected from the transaction and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with respect to the variable consideration is subsequently resolved. The estimated revenue is updated at each reporting date to reflect the current facts and circumstances. If a contract with a customer contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative stand-alone selling prices. For each separate performance obligation, it is evaluated whether control is transferred either at a point in time or over time. For performance obligations that are satisfied over time, revenue is recognized based on a measure of progress, which depicts the performance in transferring control to the customer. If under the terms of its licensing arrangements Relief provides the licensee with a research and development license, which represents a right to access Relief’s intellectual property as it exists throughout the license period, the promise to grant a license is accounted for as a performance obligation satisfied over time, as the licensee simultaneously receives and consumes the benefits of Relief’s performance. Earnings based on the collaboration partners’ gross profit, which is shared under the respective collaboration agreements, are recognized when the underlying sales occur, which is when the performance obligation has been satisfied. Relief uses certain information from its collaboration partners, some of which is based on preliminary data shared between the partners and might vary once final data is available. Revenue arrangements that involve two or more partners who contribute to the provision of a specific good or service to a customer are assessed in terms of principal-agent considerations in order to determine the appropriate treatment for the transactions between Relief, partners, and third parties. The classification of transactions under such arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which Relief is considered the principal, which includes being in control of the good or service before such good or service is transferred to the customer, is accounted for as gross revenue. Any consideration related to activities in which Relief is considered the agent, is accounted for as net revenue. Revenue from the sale of products is recognized when Relief transfers control of the product to the customer. Control of the product normally transfers when the customer gains physical possession and Relief has not retained any significant risks of ownership or future obligations with respect to the product. A receivable is recognized, as the consideration is unconditional and only the passage of time is required before payment is due. The transaction price is quoted in the relevant price lists in force at the date of the customer placing the respective order for such products. Revenue from research and development services provided by the Company is recorded as earned based on the performance requirements of the underlying contracts. Where agreements include milestones that are determined to be substantive and at risk at the inception of the agreement, revenue is recognized upon confirmation by the counterparty that the milestone has been achieved. 3.7 Foreign currency translation Functional and presentation currency Items included in the financial statements of each of the Group’s entities are measured using the currency of the primary economic environment in which the entity operates (i.e., the functional currency). The consolidated financial statements are presented in CHF, which is the presentation currency of the Group. Transactions and balances In preparing the financial statements of each group entity, transactions in currencies other than the entity’s functional currency are recognized at the rates of exchange prevailing at the dates of the transactions. At the end of each reporting period, monetary items denominated in foreign currencies are re-translated Non-monetary re-translated. Group companies Assets and liabilities of Group entities using a functional currency different from the presentation currency are translated into the presentation currency using year-end 3.8 Intangible assets Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and impairment losses. Internally generated intangibles, excluding capitalized development costs, are not capitalized and the related expenditure is reflected in profit or loss in the period in which the expenditure is incurred. The useful lives of intangible assets are assessed as either finite or indefinite. Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortization period or method, as appropriate, and are treated as changes in accounting estimates. Amortization of capitalized in process research & development (IPR&D) starts once the asset is available for use, which is usually the point in time at which marketing approval is granted by the relevant authority. Before that date, capitalized IPR&D that is not available for use is tested at least annually for impairment, irrespective of whether any indication of impairment exists. Gains or losses arising from the de-recognition 3.9 Leases The Group assesses whether a contract is or contains a lease at the inception of the contract. The Group recognizes a right-of-use The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the Group uses its incremental borrowing rate for such liabilities. Lease payments included in the measurement of the lease liability comprise: • fixed lease payments (including in-substance • variable lease payments that depend on an index or rate, initially measured using the index or rate at the commencement date; • the amount expected to be payable by the lessee under residual value guarantees; • the exercise price of purchase options, if the lessee is reasonably certain to exercise the options; and • payments of penalties for terminating the lease if the lease term reflects the exercise of an option to terminate. The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using the effective interest method) and by reducing the carrying amount to reflect the lease payments made. The right-of-use Right-of right-of-use right-of-use The Group has elected not to recognize right-of-use low-value 3.10 Financial assets Classification The Group has only financial assets classified within the categories “financial assets at fair value through profit or loss (FVTPL)” and “financial assets at amortized cost.” The classification at initial recognition depends on the financial asset’s contractual cash flow characteristics and the Group’s business model for managing them. The Group’s financial assets at amortized cost include other current assets and other receivables that are non-derivative Recognition and measurement Financial assets at amortized cost are measured initially at their fair value and are subsequently measured at amortized cost using the effective interest rate method and are subject to impairment. A financial asset is derecognized when: • the contractual rights to the cash flows from the asset have expired; or • the Group has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a pass-through arrangement; and either (a) the Group has transferred substantially all the risks and rewards of the asset, or (b) the Group has neither transferred nor retained substantially all the risks and rewards of the asset but has transferred control of the asset. Financial assets at FVTPL are measured at fair value at the end of each reporting period, with any fair value gains or losses recognized in profit or loss. Fair value is determined in the manner described in note 33. Impairment of financial assets The Group recognizes an allowance for expected credit losses (ECL) for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms. ECLs are recognized in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next twelve months (a twelve-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL). The Group considers a financial asset in default when contractual payments are 90 days 3.11 Inventories Raw materials and merchandise purchased are recognized at cost; semi-finished and finished goods at their production cost. Discounts are recognized as a reduction in the purchase price. Manufacturing costs include the associated direct production costs and production overheads, where applicable. If the acquisition or manufacturing costs are higher than the net market value, an impairment loss is recorded on the income statement in the current period to write the inventories down to the net market value (lower of cost or market principle). Net market value is equivalent to the current market price less the usual sales deductions, marketing costs and administrative costs yet to be incurred. Inventories that cannot be sold are written off in full. The costs of inventories are determined by using the FIFO method. Inventory related to drug products that have not yet obtained regulatory approval is immediately written down to zero. The write-down is charged to research and development expenses. If regulatory approval is subsequently obtained, the recorded expenses are not reversed. 3.12 Cash and cash equivalents Cash and cash equivalents include cash in hand, deposits held at call with banks and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts are shown within financial debts in current liabilities on the balance sheet. This definition is also used for the purposes of the cash flow statement. 3.13 Financial liabilities The Group’s financial liabilities include trade and other payables as well as borrowings. Financial liabilities are recognized initially at fair value and are subsequently measured at amortized cost using the effective interest rate method, with interest expense recognized on an effective yield basis. The Group derecognizes financial liabilities when, and only when, the Group’s obligations are discharged, canceled, or expired. 3.14 Current and deferred income tax The tax expense for the period comprises current and deferred tax. Tax is recognized in the income statement, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. In this case, the tax is also recognized in other comprehensive income or directly in equity, respectively. Deferred income tax is recognized, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, the deferred income tax is not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that, at the time of the transaction, affects neither accounting nor taxable profit or loss, and does not give rise to equal taxable and deductible temporary differences. Deferred income tax is determined using tax rates and applicable laws that have been enacted or substantively enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Deferred income tax is provided on temporary differences arising on investments in subsidiaries and associates, except for deferred income tax liability where the timing of the reversal of the temporary difference is controlled by the Group and it is probable that the temporary difference will not reverse in the foreseeable future. 3.15 Fair values Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either: • in the principal market for the asset or liability, or • in the absence of a principal market, in the most advantageous market for the asset or liability. The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. The fair values of financial assets and liabilities at the balance sheet date are not materially different from their reported carrying values unless specifically mentioned in the notes to the consolidated financial statements. 3.16 Research and development costs Research and development costs consist primarily of remuneration and other expenses related to research and development personnel, costs associated with preclinical testing and clinical trials of product candidates, expenses for research and development services under collaboration agreements and outsourced research and development expenses. Furthermore, the Group may acquire in-process In-process Internal development costs are capitalized as intangible assets only when there is an identifiable asset that can be completed and that will generate probable future economic benefits and when the cost of such an asset can be measured reliably. 3.17 Employee benefits General Wages, salaries, social security contributions, paid annual leave and sick leave, bonuses, and non-monetary Pension obligations The cost of providing benefits under the defined benefit plan is determined using the projected unit credit method. Re-measurements, Re-measurements Past service costs are recognized in profit or loss on the earlier of: • the date of the plan amendment or curtailment, or • the date that the Group recognizes restructuring-related costs. Net interest is calculated by applying the discount rate to the net defined benefit liability or asset. The Group recognizes the following changes in the net defined benefit obligation under ‘personnel expense’ in the statement of comprehensive income: • service costs comprising current service costs, past-service costs, gains and losses on curtailments and non-routine • net interest expense or income. 3.18 Share-based payments The cost of equity-settled transactions is determined by the fair value at the date when the grant is made using an appropriate valuation model. That cost is recognized, together with a corresponding increase in other capital reserves in equity, over the period in which the performance and/or when service conditions are fulfilled as employee benefit expenses. The cumulative expense recognized for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Group’s best estimate of the number of equity instruments that will ultimately vest. The statement of profit or loss expense or credit for a period represents the movement in cumulative expense recognized at the beginning and end of that period and is recognized in employee benefits expense. No expense is recognized for awards that do not ultimately vest, except for equity-settled transactions for which vesting is conditional upon a market or non-vesting non-vesting When the terms of an equity-settled award are modified, the minimum expense recognized is the expense as if the terms had not been modified if the original terms of the award have been met. An additional expense is recognized for any modification that increases the total fair value of the share-based payment transaction or is otherwise beneficial to the employee as measured at the date of modification. The dilutive effect of outstanding options is reflected as additional share dilution in the computation of diluted earnings per share.

Summary of critical accounting

Summary of critical accounting judgments and key sources of estimation uncertainty	12 Months Ended
	Dec. 31, 2023
Disclosure Of Critical Accounting Judgments And Key Sources Of Estimation Uncertainty [Abstract]
Summary of critical accounting judgments and key sources of estimation uncertainty	4. Summary of critical accounting judgments and key sources of estimation uncertainty The preparation of the consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income, expenses and related disclosures. The estimates and underlying assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are described below. 4.1 Critical judgments in applying accounting policies Collaboration and license agreement with Acer In March 2021, Relief and Acer Therapeutics Inc. (“Acer”) entered into a collaboration and license agreement for the worldwide development and commercialization of ACER-001 ® In August 2023, Relief and Acer terminated the March 2021 collaboration and license agreement. Concurrently, the parties entered into a new exclusive license agreement. Relief’s primary entitlement was restructured from a 60% net profit share from U.S. sales of OLPRUVA ® non-US-territories, non-refundable non-contingent ACER-001. Revenue recognition Revenue is primarily from fees related to license fees, royalties and product sales. Given the complexity of certain agreements, judgment is required to identify distinct performance obligations, allocate the transaction price to these performance obligations and determine when the performance obligations are met. Going concern These consolidated financial statements have been prepared assuming the Group will continue as a going concern which contemplates the continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business. As of December 31, 2023, the Group had cash and cash equivalents of CHF 14.6 million. Based on financial projections and available cash, the Group is expected to have sufficient resources to fund operations for at least the next twelve months. Since its inception, the Group has primarily relied on external financing to fund its cash needs and has experienced recurring losses. The Group may continue to generate operating losses in the foreseeable future. The Group’s long-term viability depends on its ability to raise additional capital until it generates positive cash flows to support its operations. The Group may never achieve sustainable profitability and is exposed to all the risks inherent in establishing a business. Management intends to continue to explore options to obtain additional funding, including public or private financing, or license and collaboration agreements. However, there can be no assurance that capital will be available in sufficient amounts or on acceptable terms. If Relief is unable to obtain the required funding, it will be forced to delay, reduce or eliminate some or all of its research and development programs and of its product portfolio expansion or commercialization efforts, which could adversely affect its business prospects or result in the Group’s inability to continue operations. 4.2 Key sources of estimation uncertainty Assessment of contingent liabilities IFRS 3 requires the recognition of contingent considerations arising from business combinations at fair value at the acquisition date. The fair value of the contingent consideration is estimated based on management’s assessment of the likelihood of the contingency occurring and the amount of payment that would be required if the contingency were to occur. Contingent considerations are subsequently measured at fair value at the end of each reporting period. The estimation of the fair value requires the use of estimates and assumptions that are subject to significant judgment, as further detailed in note 18. The Group is exposed to contingencies, including litigations and regulatory or legal proceedings, in its ordinary course of business. A provision is recognized when an outflow of resources is probable and the amount can be estimated reliably. If an outflow is not considered probable or the amount cannot be estimated reliably, no provision is recorded. The outcome of these proceedings is inherently uncertain, and assessing their likelihood and potential impact on the Group’s financial position or performance involves significant judgment. Valuation and impairment of intangible assets Determining whether intangible assets and goodwill are impaired requires management to estimate the recoverable value of the cash-generating unit to which the intangible assets are attributable. If the recoverable value of the cash-generating unit is lower than the carrying amount of the cash-generating unit to which the intangible assets have been allocated, an impairment allowance is recorded. Changes to the assumptions may result in additional impairment losses or impairment reversals in subsequent periods. Further details regarding the valuation methods used and the key assumptions and judgments made in relation to intangible assets and goodwill are provided in note 7. Share-based compensation The fair values of the options at the grant date are assessed using the Black-Scholes valuation model and are spread over the applicable vesting period of each option. The amount recognized as an expense in the income statement represents the value of the services received during the reporting period in exchange for the options granted. The fair value of the options granted is estimated at the grant date based on the Black-Scholes valuation model. The main inputs subject to estimation used in the model are the expected life of each option and the volatility of the underlying share. Deferred income tax assets The recoverability of deferred income tax assets is assessed based on management’s judgment, taking into consideration the Group companies’ forecasted future taxable profits that are subject to uncertainty. Deferred income tax assets are recognized only to the extent that it is probable that taxable profits will be available against which the deductible temporary differences and carried forward losses can be utilized. The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. The assessment of the recoverability of deferred tax assets requires significant judgment and involves the use of assumptions and estimates regarding future taxable profits. The Group considers all available positive and negative evidence when assessing the recoverability of deferred tax assets, including historical profitability, future plans, and reasonable and supportable forecasts of future taxable profits. Defined benefit obligations A retirement benefit obligation for personnel is recognized based on various financial and actuarial assumptions. The key assumptions used to assess these obligations are the discount rate, future salary increases, future pension increases, and the probability of the employee reaching retirement. An actuarial expert performed the calculations, and the principal assumptions used are summarized in note 17.

Group companies

Group companies	12 Months Ended
	Dec. 31, 2023
Disclosure Of Composition Of Group [Abstract]
Group companies	5. Group companies The following table lists subsidiaries controlled by Relief at the end of the reporting period. Name Country Location Equity interest 2023 2022 Relief Therapeutics International SA Switzerland Geneva 100 % 100 % Relief Therapeutics US, Inc. United States Connecticut 100 % 100 % Relief Therapeutics, Inc. United States Delaware 100 % 100 % APR Applied Pharma Research SA Switzerland Balerna 100 % 100 % APR Applied Pharma Research Holding SA Switzerland Balerna 100 % 100 % APR Applied Pharma Research - Italy s.r.l. Italy Monza 100 % 100 % APR Applied Pharma Research Deutschland GmbH Germany Offenbach am Main 100 % 100 % AdVita Lifescience GmbH Germany Freiburg im Breisgau 100 % 100 % AdVita Lifescience AG Switzerland Basel 100 % 100 % AdVita Lifescience, Inc. United States New York 100 % 100 % The equity interest percentage shown in the table also represents the share in voting rights in those entities as of December 31, 2023 and 2022.

Segment information

Segment information	12 Months Ended
	Dec. 31, 2023
Disclosure of operating segments [abstract]
Segment information	6. Segment information 6.1 Description of segment The Group operates in one segment, namely research, development and commercialization of biopharmaceutical products. The Board of Directors and the Executive Committee, being together the chief operating decision maker, allocate resources and assess the performance of the Group at a consolidated level. The accounting policies used for segment reporting are the same as those used for the preparation of these financial statements. 6.2 Information on revenue The Group generates revenue primarily from sales of products and out-licensing The disaggregation of the Group’s revenue is presented in the following table. Revenue is reported by geographical location based on the location of the customer or licensee and, for R&D services, based on the location where the services were performed. TCHF 2023 2022 Revenue streams Royalties 1,411 2,482 Product sales 4,256 2,525 Licensing fees 19 380 Revenue from research and development services 347 694 Total revenue 6,033 6,081 Geographical area Switzerland 414 800 Europe (excluding Switzerland) 2,886 2,412 North America 1,406 1,699 Rest of the world 1,327 1,170 Total revenue 6,033 6,081 Timing of revenue recognition Point in time 6,033 6,081 Over time —  —  Total revenue 6,033 6,081 6.3 Geographical location of non-current TCHF December 31, 2023 December 31, 2022 Switzerland 57,189 165,484 Rest of the world 193 122 Total non-current 57,382 165,606 * Without financial assets and deferred tax assets

Intangible assets

Intangible assets	12 Months Ended
	Dec. 31, 2023
Disclosure Of Intangible Assets And Goodwill [Abstract]
Intangible assets	7. Intangible assets TCHF Technologies, patents and Licenses In-process Goodwill Total Historical cost January 1, 2022 39,357 13,729 132,395 8,658 194,139 Addition 174 —  314 —  488 December 31, 2022 39,531 13,729 132,709 8,658 194,627 Acquisition price adjustment —  —  (188 ) —  (188 ) Divestment —  (9,747 ) —  (455 ) (10,202 ) December 31, 2023 39,531 3,982 132,521 8,203 184,237 Accumulated amortization and impairment January 1, 2022 (1,840 ) —  —  —  (1,840 ) Amortization (3,448 ) —  —  —  (3,448 ) Impairment (24,255 ) —  (529 ) (1,640 ) (26,424 ) December 31, 2022 (29,543 ) —  (529 ) (1,640 ) (31,712 ) Amortization (1,930 ) (752 ) —  —  (2,682 ) Impairment —  —  (89,878 ) (6,017 ) (95,895 ) Divestment —  466 —  —  466 December 31, 2023 (31,473 ) (286 ) (90,407 ) (7,657 ) (129,823 ) Carrying amount per class December 31, 2022 9,988 13,729 132,180 7,018 162,915 December 31, 2023 8,058 3,696 42,114 546 54,414 Carrying amount per asset PKU GOLIKE 4,344 —  —  —  4,344 Diclofenac 3,714 —  —  360 4,074 ACER-001 —  3,696 —  186 3,882 RLF-100 —  —  17,130 —  17,130 RLF-TD011 —  —  24,858 —  24,858 Sentinox —  —  —  —  —  RLF-OD032 —  —  126 —  126 December 31, 2023 8,058 3,696 42,114 546 54,414 PKU GOLIKE 4,678 —  —  —  4,678 Diclofenac 5,310 —  —  360 5,670 ACER-001 —  13,729 —  641 14,370 RLF-100 —  —  81,516 3,805 85,321 RLF-TD011 —  —  47,392 2,212 49,604 Sentinox —  —  2,958 —  2,958 RLF-OD032 —  —  314 —  314 December 31, 2022 9,988 13,729 132,180 7,018 162,915 Intangible assets include acquired patents, trademarks, licenses, technologies and other assets without physical substance. These items are measured at cost less accumulated amortization and impairment. The cost of an intangible asset acquired in a business combination corresponds to its estimated fair value at the date of the acquisition. 7.1 Technologies, patents and trademarks These intangible assets relate to the following on-market • PKU GOLIKE ® • Diclofenac-based products, a product line indicated for the treatment of inflammatory conditions and pain management. These products are commercialized by third parties under different brand names, including Cambia ® ® ® The acquisition costs are amortized over the estimated remaining useful lives of the assets, which range from approximately 2 to 13 years with a weighted average of 8.5 years as of December 31, 2023. Amortization is charged on a straight-line basis over the estimated economic or legal useful life, whichever is shorter. 7.2 Licenses The intangible asset is the acquisition cost of licensing and royalty rights for the development and commercialization of ACER-001. ACER-001 ACER-001 ® Pursuant to the August 2023 termination and license agreements, Relief is entitled to receive from Acer a 10% continuing royalty on net sales of OLPRUVA in the Acer territory (worldwide, excluding Europe), and 20% of any value received by Acer from licensing or divestment transactions relating to OLPRUVA, up to a cumulative amount of USD 45 million (CHF 37.9 million). Relief committed to paying Acer a variable, continuing royalty up to a maximum of 10% of potential future net sales of OLPRUVA in Europe and 20% of any value received by Relief from sublicensing transactions relating to OLPRUVA. The termination of the March 2021 collaboration and license agreement was accounted for as a partial disposal of the asset (note 4.1). Based on internal valuation models, the Group determined that the transaction resulted in a notional reduction of 71% in the risk-adjusted future economic benefits expected from the license. As a result, 71% of the net carrying amount of the asset was derecognized on the date of the transaction. In addition, a corresponding portion of goodwill allocated to ACER-001 non-contingent one-year The intangible asset associated with the ACER-001 7.3 In-process IPR&D assets mainly relate to the following programs: • RLF-100 ® • RLF-TD011, ™ RLF-TD011 • RLF-OD32, RLF-OD32, IPR&D assets are indefinite-life intangible assets until completion or abandonment of the associated research and development programs. Amortization will commence when the assets become available for use, generally once regulatory and marketing approvals are obtained. 7.4 Goodwill A goodwill of TCHF 8,658 was recognized through the acquisition of APR in 2021. The goodwill was recognized at cost on the acquisition date for the difference between the consideration transferred and the net fair value of assets, liabilities and contingent liabilities identified in the purchase price allocation. The Group had identified that the group of cash-generating units (CGUs) constituting the sole operating segment (note 6.1) was expected to benefit from the combination. Accordingly, goodwill was allocated to this group of CGUs. Since the acquisition date, goodwill was impaired by TCHF 7,657 due to impairments recognized on certain underlying CGUs and was partially disposed of by TCHF 455 in relation to the renegotiation of the Acer license agreement. 7.5 Impairment test Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. Intangible assets with indefinite useful lives are not amortized but are tested for impairment either individually or at the cash-generating unit level. The Group generally tests its intangible assets for impairment at the end of the year, or more frequently if events or changes in circumstances indicate that intangible assets may be impaired. In 2023, the Group identified circumstances that negatively affected the recoverable value of its assets in development and, potentially, of certain of its assets associated with marketed products. Consequently, the Group conducted an impairment test of its significant intangible assets and goodwill as of December 31, 2023. For the purpose of impairment testing, goodwill was allocated to each CGU constituting the sole operating segment of the Group. The recoverable amount of the group of CGUs is based on the cumulated value in use estimated for each CGU or group of CGUs. The Group’s material CGUs relate to the on-market Key assumptions used in value in use calculations The estimation of recoverable amounts involves significant management judgment. The values assigned to each assumption on an asset basis are based on historical data from external and internal sources and on management’s estimates. The key assumptions used in the valuation models were determined as follows: • Cash flow projections were based on a financial forecast developed by management, which includes projections for net sales, cost of sales, licensing fees, and development costs. These projections are periodically reviewed and updated by management. • Revenue projections were based on a product-specific analysis that considered relevant market sizes, disease prevalence, incidence rates, expected market share, expected patent life, expected licensing terms, and the expected year of regulatory approval for unapproved product candidates based on the current stage of development and expected development plan. • Forecast periods were defined on a product basis and based on product life cycles. For on-market in-process • Probabilities of success for tested IPR&D assets, which are associated with projects in process aiming to reach final development and commercialization, ranged from 12% to 35%. These probabilities were based on empirical success rate analysis of multi-stage studies for comparable indications, or if this approach could not be applied, management exercised its judgment. • The pre-tax Impairment test conclusion Relief conducted a comprehensive strategic review and initiated in the fourth quarter of 2023 its transition from a direct marketing and sales infrastructure to a partnership-based model. This pivotal shift, alongside additional knowledge gained during the year into the development requirements for the Group’s IPR&D assets, necessitated adjustments in projected development costs and timelines. The Group revised its commercialization and development plans accordingly. For the year ended December 31, 2023, the Group recognized a non-cash RLF-100, RLF-TD011 Impairment charges of TCHF 64,386 for RLF-100 RLF-TD011 For other intangible assets and remaining goodwill, the Group determined based on the results of the impairment test that their estimated value in use exceeded their respective carrying amounts as of the measurement date. Therefore, the Group did not record an impairment charge on these other assets. Sensitivity to changes in assumptions The Group performed a sensitivity analysis taking into account reasonably possible changes in the assumptions the value in use is most sensitive to, as listed in the key assumptions section above, including higher discount rate, lower projected income, increased development budget, and postponed market launch when applicable. The intangible assets associated with RLF-100 RLF-TD011 For intangible assets associated with PKU GOLIKE, OLPRUVA, and Diclofenac, the Group concluded that no reasonably possible change of key assumptions would cause the carrying amount to exceed the recoverable amount. While management believes the assumptions used are reasonable, changes in these assumptions could result in a future material impairment. The completion of the development of IPR&D assets is subject to the availability of capital, which is uncertain as discussed in note 4.1 of these consolidated financial statements. If the Group is unable to secure sufficient capital, it will be forced to delay or abandon certain development activities, which could lead to a material impairment of the affected assets.

Leases

Leases	12 Months Ended
	Dec. 31, 2023
Presentation of leases for lessee [abstract]
Leases	8. Leases 8.1 Right-of-use TCHF Building Equipment Total Historical cost January 1, 2022 2,538 139 2,677 Addition —  549 549 Foreign exchange difference (9 ) (2 ) (11 ) December 31, 2022 2,529 686 3,215 Addition 86 468 554 Disposal (89 ) (46 ) (135 ) Foreign exchange difference (6 ) (2 ) (8 ) December 31, 2023 2,520 1,106 3,626 Accumulated depreciation January 1, 2022 (147 ) (32 ) (179 ) Depreciation (292 ) (105 ) (397 ) Foreign exchange difference 3 —  3 December 31, 2022 (436 ) (137 ) (573 ) Depreciation (285 ) (252 ) (537 ) Disposal 41 11 52 Foreign exchange difference 1 1 2 December 31, 2023 (679 ) (377 ) (1,056 ) Carrying amount at December 31, 2022 2,093 549 2,642 at December 31, 2023 1,841 729 2,570 The Group leases various assets, including office equipment, laboratory equipment, cars, and office buildings in Switzerland, the U.S., Italy, and Germany. The remaining expected lease terms for these assets range between 1 year and 9 years. Except for office and laboratory equipment, the Group does not have an option to purchase the assets at the end of the lease term. 8.2 Maturity of lease liabilities TCHF December 31, 2023 December 31, 2022 < 1 year 524 444 1-5 1,824 1,455 > 5 years 262 777 Total 2,610 2,676 8.3 Amounts recognized in profit or loss TCHF December 31, 2023 December 31, 2022 Lease expense for short-term and low value leases 54 182 Depreciation expense on right-of-use 537 392 Interest expense on lease liabilities (note 29) 27 33 8.4 Further information on leases The Group has no material, non-cancellable

Property and equipment

Property and equipment	12 Months Ended
	Dec. 31, 2023
Disclosure of detailed information about property, plant and equipment [abstract]
Property and equipment	9. Property and equipment The net carrying amount of property and equipment increased to TCHF 397 as of December 31, 2023, from TCHF 49 as of December 31, 2022, primarily in relation to the acquisition of laboratory and office equipment.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2023
Inventories [Abstract]
Inventories	10. Inventories TCHF December 31, 2023 December 31, 2022 Raw material 2,728 2,758 Finished goods 656 139 Gross inventories 3,384 2,897 Valuation allowance (2,827 ) (2,670 ) Total 557 227 As of the reporting date, the Company’s inventory is mainly constituted by the Aviptadil active ingredient valued at its acquisition cost of TCHF 2,659. As the Aviptadil was manufactured prior to obtaining regulatory approval, the inventory was fully impaired in prior reporting periods. The remaining inventory consists mainly of active pharmaceutical ingredients and finished products for market supply.

Trade receivables

Trade receivables	12 Months Ended
	Dec. 31, 2023
Disclosure of trade receivables [Abstract]
Trade receivables	11. Trade receivables TCHF December 31, 2023 December 31, 2022 Current receivables 1,419 1,548 Expected credit loss allowance (248 ) (227 ) Total 1,171 1,321 Trade receivables do not bear interest and generally have maturities ranging from 30 and 90 days. Expected credit loss allowance The Group uses a provision matrix to estimate the expected credit losses from trade receivables outstanding at the end of the reporting period. The provision rates are based on days past due of customer invoices. The provision is initially based on the Group’s historical observed default rates. The Group calibrates the matrix to adjust the historical credit losses with forecasts on economic conditions or similar forecast data for the various geographical areas at each reporting date. TCHF 2023 2022 Balance at beginning of year (227 ) (204 ) Impairment losses recognized (36 ) (23 ) Reversal of impairment losses 15 —  Balance at end of year (248 ) (227 )

Other current assets

Other current assets	12 Months Ended
	Dec. 31, 2023
Disclosure Of Other Current Assets [Abstract]
Other current assets	12. Other current assets TCHF December 31, 2023 December 31, 2022 Other receivable (note 7.2) 972 —  Accrued revenue 501 723 Prepaid expenses 345 836 VAT receivable 168 147 Deposits 9 28 Other current receivables 25 64 Total 2,020 1,798

Cash and cash equivalents

Cash and cash equivalents	12 Months Ended
	Dec. 31, 2023
Cash and cash equivalents [abstract]
Cash and cash equivalents	13. Cash and cash equivalents As of December 31, 2023, and December 31, 2022, cash and cash equivalents consisted of cash in bank and short-term deposits.

Share capital

Share capital	12 Months Ended
	Dec. 31, 2023
Disclosure of classes of share capital [abstract]
Share capital	14. Share capital Number of shares Common shares Treasury shares Total Balance at January 1, 2022 11,033,337 (749,669 ) 10,283,668 Issuance of treasury shares 3,000,000 (3,000,000 ) —  Direct Share Placement program —  347,145 347,145 Milestone payments —  375,500 375,500 Exercises of options 7,500 —  7,500 Balance at December 31, 2022 14,040,837 (3,027,024 ) 11,013,813 Balance at January 1, 2023 14,040,837 (3,027,024 ) 11,013,813 Direct Share Placement program —  24,947 24,947 Private placements —  1,200,000 1,200,000 Exercise of pre-funded —  300,000 300,000 Withdrawal of fractional shares —  (3,009 ) (3,009 ) Exercises of options —  4,688 4,688 Balance at December 31, 2023 14,040,837 (1,500,398 ) 12,540,439 14.1 Issued share capital As of December 31, 2023, the share capital consisted of 14,040,837 issued, fully paid shares with a par value of CHF 4.00 each. The Company held 1,500,398 Reverse stock split On May 5, 2023, RELIEF THERAPEUTICS Holding SA effected a 1-for-400 pre-reverse pre-reverse As a result of the reverse stock split, all references in these financial statements to units of shares or per share amounts are reflective of the reverse split for all periods presented. In addition, the exercise prices and the numbers of shares issuable upon the exercise of any outstanding options, warrants, and other securities entitling their holders to purchase or receive Relief shares were proportionally adjusted. Equity transactions in 2023 In 2023, the following transactions resulted in cash gross proceeds of TCHF 5,116 before deducting transaction costs of TCHF 494. • June 2023 private placement: On June 15, 2023, the Company entered into a securities purchase agreement pursuant to which the Company agreed to sell in a private placement 1,200,000 ordinary shares, pre-funded Each of the warrants represents the right to purchase one ordinary share of the Company. The pre-funded Relief committed to reserving from its treasury shares reserve the maximum number of shares to be issued upon exercise of the warrants. • Direct Share Placement program: sale of 24,947 shares at an average price per share of CHF 4.07 for total gross proceeds of TCHF 102. • Exercises of options: issuance upon exercise of 4,688 shares at CHF 4.00 per share for gross proceeds of TCHF 19. The Company retired fractional shares upon completion of the reverse stock split. Fractional shares representing 3,009 shares post-reverse stock split were acquired in May 2023 for a total cost of TCHF 22. Equity transactions in 2022 In 2022, the following capital increase transactions resulted in cash gross proceeds of TCHF 7,111 before deducting transaction costs of TCHF 223. • Direct Share Placement program: sale of 347,145 shares at an average price per share of CHF 20.32 for total gross proceeds of TCHF 7,051. • Exercises of options: issuance upon exercise of 7,500 shares at CHF 8.00 per share for gross proceeds of TCHF 60. In addition, the Company made a payment in shares of TCHF 4,200, corresponding to 375,500 shares at CHF 11.20 per share, as settlement of a milestone payment obligation under the APR acquisition agreement. The Company issued a total of 3,000,000 treasury shares from its authorized capital during the year 2022. The shares were entirely subscribed to at par value by a wholly owned subsidiary for subsequent placements. 14.2 Capital band Pursuant to changes in the Swiss Code of Obligations effective January 1, 2023, and the decision of the extraordinary general meeting held on April 28, 2023, the Company’s authorized capital was replaced by a capital band. The capital range can be used for the issuance of shares for strategic acquisitions and financing transactions. As of December 31, 2023, the Board of Directors was authorized, at any time until 30 May 2024, to increase the share capital by the issuance of up to 2,500,000 ordinary shares with a nominal value of CHF 4.00, under the terms and conditions set forth in article 3a ter 14.3 Conditional share capital The conditional share capital of the Company as of December 31, 2023, was TCHF 16,688, consisting of 4,171,924 shares with a par value of CHF 4.00 each, of which 264,424 shares to be used for stock options and 3,907,500 shares for grant of option rights in connection with bonds, notes or similar financial instruments issued by the Company. 14.4 Outstanding options and warrants As of December 31, 2023, there were 126,032 outstanding stock options under the Company’s stock option plans and 1,500,000 outstanding warrants as issued in the June 2023 private placement. In addition, the Company was committed to issuing 320,000 stock options. Each stock option allows its holder to acquire one share at a predetermined price, subject to certain vesting conditions. Further information about outstanding options is provided in note 31.

Reserves

Reserves	12 Months Ended
	Dec. 31, 2023
Disclosure of reserves within equity [abstract]
Reserves	15. Reserves TCHF December 31, 2023 December 31, 2022 Share premium (note 15.1) 214,180 215,688 Share-based payment reserve (note 15.2) 5,371 4,557 Foreign currency translation reserve (note 15.3) 779 716 Total 220,330 220,961 15.1 Share premium TCHF 2023 2022 Balance at beginning of year 215,688 207,521 Net paid-in (1,014 ) 8,390 Transaction cost in relation to capital increases (494 ) (223 ) Balance at end of year 214,180 215,688 15.2 Share-based payment reserve TCHF 2023 2022 Balance at beginning of year 4,557 2,371 Share-based payments (note 31) 814 2,186 Balance at end of year 5,371 4,557 15.3 Foreign currency translation reserve TCHF 2023 2022 Balance at beginning of year 716 255 Exchange differences arising on translating foreign operations 63 461 Balance at end of year 779 716

Borrowings

Borrowings	12 Months Ended
	Dec. 31, 2023
Disclosure of detailed information about borrowings [abstract]
Borrowings	16. Borrowings As of December 31, 2023 and 2022, the company had two outstanding bank loans: a TCHF 331 loan from a German bank carrying interest at 2.7% per year and repaid in January 2024

Defined benefit obligations

Defined benefit obligations	12 Months Ended
	Dec. 31, 2023
Disclosure of information about defined benefit plans [abstract]
Defined benefit obligations	17. Defined benefit obligations The following table provides information on the amounts recognized in the balance sheet: TCHF December 31, 2023 December 31, 2022 Present value of pension benefit obligation 4,517 4,044 Fair value of pension plan assets (3,532 ) (3,494 ) Net pension defined benefit obligation 985 550 Present value of other benefit obligations 604 1,222 Total defined benefit obligations 1,589 1,772 17.1 Defined benefit plan Swiss pension plans shall be administered by a separate pension fund legally distinct from the Company. The law prescribes certain minimum benefits. The pension plans of the employees of the parent entity and its Swiss subsidiaries are carried out by collective funds with Swiss Life Collective Foundation and Caisse Inter-Entreprises de Prévoyance Professionnelle. Under these pension plans, the employees are entitled to retirement benefits and insurance for death and disability risks. In accordance with IAS 19, the above-mentioned pension plans are classified as defined benefit plans. The pension plans are described in detail in the corresponding statutes and regulations. The contributions of employers and employees, in general, are defined in percentages of the insured salary. The retirement pension is calculated based on the old-age The pension funds can change their financing system (contributions and future payments) at any time. Also, when there is a deficit that cannot be eliminated through other measures, the pension funds can oblige the Company to pay a restructuring contribution. As of December 31, 2023, such a deficit currently could not occur as the plans were fully reinsured. However, the pension funds could cancel the contracts and the entities of the Group would have to join another pension fund. In the current and comparative periods no material plan amendments, curtailments or settlements occurred. The fully reinsured pension funds have concluded insurance contracts to cover biometric and investment risks. The board of each pension fund is responsible for the investment of assets and the investment strategies are defined for the benefits to be paid out when due. The actuarial valuation of plan assets and the present value of the defined benefit obligation were carried out on December 31, 2023. The present value of the defined benefit obligation, the related current service cost, and the past service cost were measured with the projected unit credit method. The amounts recognized in profit or loss for these defined benefit plans were as follows: TCHF 2023 2022 Net service cost 212 207 Net interest expense 7 4 Administration cost excl. cost for managing plan assets 31 23 Expense recognized in profit or loss 250 234 The amounts recognized in other comprehensive income for these defined benefit plans were as follows: TCHF 2023 2022 Remeasurement (gain)/loss on defined benefit obligation due to changes in demographic assumptions (11 ) —  due to changes in financial assumptions 426 (1,150 ) due to changes in experience adjustments (31 ) 156 Return on plan assets excl. interest income 100 52 Expense/(Income) recognized in other comprehensive income 484 (942 ) The movements in the present value of the defined benefit obligation were as follows: TCHF 2023 2022 Opening defined benefit obligation 4,044 4,496 Net service cost 212 207 Interest expense on defined benefit obligation 85 13 Contributions from plan participants 129 129 Benefits (paid)/deposited (337 ) 193 Remeasurement (gain)/loss due to changes in demographic assumptions (11 ) —  Remeasurement (gain)/loss due to changes in financial assumptions 426 (1,150 ) Remeasurement (gain)/loss due to changes in experience adjustments (31 ) 156 Closing defined benefit obligation 4,517 4,044 Movements in the present value of the plan assets in the current period were as follows: TCHF 2023 2022 Opening fair value of plan assets 3,494 2,946 Interest income on plan assets 78 9 Return on plan assets excluding interest income (100 ) (52 ) Contributions from the employer 299 292 Contributions from plan participants 129 129 Benefits (paid)/deposited (337 ) 193 Administration cost (31 ) (23 ) Closing fair value of plan assets 3,532 3,494 The respective insurance companies provide reinsurance of these assets and bear all market risk on these assets. The actual return on plan assets was TCHF (22) (2022: TCHF (43)). Principal assumptions used for the purposes of the actuarial valuations were as follows: TCHF 2023 2022 Discount rate          1.40 %       2.15 % Expected rate of salary increase 1.90 % 1.50 % Sensitivity analyses based on reasonably possible changes in key assumptions indicated that: • a 25 basis points increase (decrease) in the discount rate, holding all other assumptions constant, would result in a 3.7% decrease (3.9% increase) in the defined benefit obligation; and • if the expected salary growth rate increases (decreases) by 0.25%, with other assumptions remaining constant, the defined benefit obligation would increase by 0.6% (decrease by 0.6%). The average duration of the defined benefit obligation at the end of the reporting period was 15.2 years (2022: 14.4 years). Total pension contributions by the Group to its pension plans for the 2024 financial year are expected to amount to TCHF 289. 17.2 Other employee benefits The obligations for other employee benefits mainly consist of end of service indemnities, which do not have the character of pensions, and are classified as a defined benefit plan in accordance with IAS 19.

Provisions

Provisions	12 Months Ended
	Dec. 31, 2023
Provisions [abstract]
Provisions	18. Provisions TCHF Contingent consideration (i) Legal and regulatory (ii) Other (iii) Total Balance at December 31, 2022 10,867 136 —  11,003 Addition —  —  235 235 Unwinding of discount on provisions 303 —  —  303 Variation due to assumption adjustment (4,782 ) —  —  (4,782 ) Foreign exchange difference (185 ) —  —  (185 ) Utilization —  (136 ) —  (136 ) Balance at December 31, 2023 6,203 —  235 6,438 thereof current —  —  235 235 thereof non-current 6,203 —  —  6,203 (i) Contingent consideration for business acquisitions As of December 31, 2023, the Group recognized provisions of TCHF 6,203 for contingent payments that may become due to the former shareholders of APR and AdVita upon completion of pre-agreed Contingent consideration for the acquisition of APR As of December 31, 2023, the remaining milestone payments under the acquisition agreement were (i) the execution of a definitive agreement for the commercialization of Sentinox ™ RLF-TD011 Contingent consideration for the acquisition of AdVita As of December 31, 2023, the remaining milestone payments under the acquisition agreement were (i) the approval in the U.S. or Europe of the inhaled form of Aviptadil for the treatment of sarcoidosis or berylliosis, and (ii) the conduct of a phase II clinical study for the inhaled form of Aviptadil in the treatment of checkpoint inhibitor-induced pneumonitis. Contingent payments aggregate to a maximum amount of EUR 10 million (CHF 9.3 million), in cash. Provisioned amounts are calculated at the end of each reporting period by determining the probability-weighted present value of potential payments. As of December 31, 2023, probabilities ranged from 12% to 75% based on the estimated likelihood of completion for each underlying milestone. These probabilities are consistent with those estimated for the impairment test conducted for intangible assets and goodwill (note 7). Time to completion of each milestone ranged from approximately four years to nine years. A discount rate of 5% was determined based on the estimated time value of comparable liabilities, excluding risks factored into the probabilities of success. (ii) Legal and regulatory proceedings SIX Exchange Regulation A provision of TCHF 136 was released upon the conclusion in 2023 of an investigation initiated in 2021 by SIX Exchange Regulation AG. The actual cost amounted to TCHF 142. Other legal and regulatory proceedings In the ordinary course of business, the Group is subject to potential liabilities arising from litigations and other disputes. As of December 31, 2023, there was no litigation considered to have a reasonably possible or probable impact that could result in a material loss to the Group. (iii) Other As of December 31, 2023, the Group constituted provisions totaling TCHF 235 for remaining termination costs anticipated in connection with the transition from a direct marketing and sales infrastructure to a partnership-based model initiated in 2023.

Financial liabilities due to re

Financial liabilities due to related parties	12 Months Ended
	Dec. 31, 2023
Disclosure of Financial Liabilities Due to Related Parties [Abstract]
Financial liabilities due to related parties	19. Financial liabilities due to related parties In January 2021, the Company signed a financing agreement with its largest shareholder, GEM Global Yield LLC SCS and GEM Yield Bahamas Limited (“GEM”), for the implementation of a share subscription facility (the “SSF”) in the amount of up to CHF 50 million until January 20, 2024. As of December 31, 2023, the Company had not drawn on the SSF. The Company agreed to pay GEM a commitment fee (the “Fee”) of TCHF 1,250 plus accrued interest. As of December 31, 2023, the Fee was payable on demand and bore interest at 1% above the base rate of Barclays Bank plc. As the obligation to pay the Fee arose with the execution of the agreement, the Company recorded it in full as a liability on the signature date. The corresponding expense is recognized as financial expense (note 29) over the SSF commitment period of three years ending January 20, 2024.

Other current payables and liab

Other current payables and liabilities	12 Months Ended
	Dec. 31, 2023
Disclosure of other current payables and liabilities [Abstract]
Other current payables and liabilities	20. Other current payables and liabilities TCHF December 31, 2023 December 31, 2022 Accrued expenses 1,736 2,138 Personnel-related accruals and payables 1,049 497 Stamp duty and capital tax liabilities 51 347 Deferred revenue 114 776 Other current liabilities 483 143 Total 3,433 3,901

Other gains

Other gains	12 Months Ended
	Dec. 31, 2023
Expenses by nature [abstract]
Other Gains	21. Other gains TCHF 2023 2022 Divestment gain (note 7.2) 125 —  Income from sublease agreements 99 94 Reversal of impairment on financial assets —  453 Reversal of impairment on other receivables 58 235 Various others 13 247 Total other gains 295 1,029

Cost of sales

Cost of sales	12 Months Ended
	Dec. 31, 2023
Revenue [abstract]
Cost of Sales	22. Cost of sales Expenses incurred with third parties in relation to the purchase and manufacturing of drug products for sale, as well as laboratory supplies in connection with research and development services provided to customers, are classified in ‘raw materials and consumables expenses’. Expenses incurred with third parties in relation to advertising, marketing, sales promotion, shipping, distribution and commission on sales, are classified as ‘external selling and distribution expenses’. The consolidated statement of comprehensive loss aggregates transactions according to their nature. The overall cost of sales, which includes internal and external expenses of different natures, is therefore not presented in a distinct line. The increase in ‘raw materials and consumables expenses’ correlates with the increase in revenue from product sales. A change in the product mix, with a higher proportion of sales stemming from higher-margin products, reduced the ratio of raw materials and consumables expenses over product sales. External selling and distribution expenses decreased mainly due to scaled-back marketing activities in 2023, following the preparation and launch of PKU GOLIKE ®

External research and developme

External research and development expenses	12 Months Ended
	Dec. 31, 2023
Disclosure Of Research And Development Expense Explanatory [Abstract]
External research and development expenses	23. External research and development expenses External research and development expenses include costs associated with outsourced clinical research organization activities, sponsored research studies, clinical trial costs, process development, and product manufacturing expenses in relation to research and development programs. In 2023, external research and development expenses mainly comprised the external development costs associated with RLF-OD032, RLF-100 RLF-TD011,

Personnel expenses

Personnel expenses	12 Months Ended
	Dec. 31, 2023
Classes of employee benefits expense [abstract]
Personnel expenses	24. Personnel expenses TCHF 2023 2022 Salaries and social security expense 11,088 10,513 Independent contractors fees —  320 Share-based payment expense (note 31) 814 2,186 Service cost for other benefit obligations (64 ) (21 ) Total personnel expenses 11,838 12,998

Other administrative expenses

Other administrative expenses	12 Months Ended
	Dec. 31, 2023
Disclosure Of Administrative Expenses [Abstract]
Other Administrative Expenses	25. Other administrative expenses TCHF 2023 2022 Professional services 2,918 6,053 Other administrative expenses 2,473 1,694 Total other administrative expenses 5,391 7,747 Professional services primarily include expenses incurred in relation to legal, communication, listing, accounting and audit services, as well as other consulting activities not related to research and development. Other administrative expenses comprise IT, travel, insurances, IP maintenance and prosecution, and various other expenses. The decrease in professional services expenses is mainly attributable to a reduction in legal and regulatory affairs expenses, driven by non-recurring

Other losses

Other losses	12 Months Ended
	Dec. 31, 2023
Disclosure Of Other Losses [Abstract]
Other losses	26. Other losses Other losses in 2023 and 2022 related to impairment losses on financial assets.

Impairment expense

Impairment expense	12 Months Ended
	Dec. 31, 2023
Disclosure Of Impairment Expenses [Abstract]
Impairment expense	27. Impairment expense TCHF 2023 2022 Impairment losses on intangible assets (note 7) 95,895 26,424 Impairment losses on inventories (note 10) 184 —  Total impairment expense 96,079 26,424

Amortization and depreciation e

Amortization and depreciation expense	12 Months Ended
	Dec. 31, 2023
Depreciation and amortisation expense [abstract]
Amortization and depreciation expense	28. Amortization and depreciation expense TCHF 2023 2022 Amortization of intangible assets (note 7) 2,682 3,448 Depreciation of rights-of-use 537 392 Depreciation of property and equipment (note 9) 99 20 Total amortization and depreciation expense 3,318 3,860

Financial income and expenses

Financial income and expenses	12 Months Ended
	Dec. 31, 2023
DisclosureOfFinanceIncomeExpense [Abstract]
Financial income and expenses	29. Financial income and expense TCHF 2023 2022 Interest income on cash deposits 64 —  Interest income on deferred payment (note 7.2) 29 —  Interest income on loans —  18 Total financial income 93 18 Unwinding of discount on provisions (note 18) (303 ) (1,308 ) SSF commitment fee (note 19) (417 ) (416 ) Negative interest on cash deposits —  (93 ) Interest expense related to leases (note 8) (27 ) (33 ) Bank charges (20 ) (40 ) Foreign exchange loss, net (65 ) (374 ) Other financial expenses (117 ) (30 ) Total financial expense (949 ) (2,294 )

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Disclosure Of Income Tax [Abstract]
Income Taxes	30. Income taxes 30.1 Income tax recognized in profit or loss TCHF 2023 2022 Current tax Current tax expense for the year —  —  Adjustments in current tax of prior years —  —  —  —  Deferred tax Deferred tax income for the year (13,503 ) (4,977 ) Write-down of deferred tax assets —  1,451 (13,503 ) (3,526 ) Net income tax gain (13,503 ) (3,526 ) The income tax gain of TCHF 13,503 is primarily related to a reduction in deferred tax liabilities resulting from the impairment and amortization expenses recognized against intangible assets (note 7). The following table provides a reconciliation between the income tax gain recognized for the year and the tax calculated by applying the applicable tax rates on the net result before income taxes. TCHF 2023 2022 Loss before tax (111,684 ) (54,316 ) Income tax expense calculated at 13.99% (2022: 13.99%) (15,625 ) (7,599 ) Unrecognized deferred tax assets during the year 2,138 4,235 Write-down of deferred tax assets —  1,451 Effect of deferred tax balances due to difference in applicable tax rates 24 (802 ) Effect of net (income)/expense that is not added/(deductible) (40 ) (811 ) Income tax recognized in the current year (13,503 ) (3,526 ) As of December 31, 2023, the applicable tax rate of the Group was 13.99% (2022: 13.99%), which was equal to the statutory tax rate of the holding company. 30.2 Income tax recognized in other comprehensive income In 2023 and 2022, no income tax was recognized in the statement of other comprehensive income. 30.3 Deferred tax balance The following table sets out the changes in deferred tax assets and liabilities: 2023 TCHF Opening balance Recognized in OCI Recognized in profit or loss Closing balance Tax losses 495 —  94 589 Total deferred tax assets 495 —  94 589 Intangible assets 20,736 —  (13,370 ) 7,366 Total deferred tax liabilities 20,736 —  (13,370 ) 7,366 2022 TCHF Opening balance Recognized in OCI Recognized in profit or loss Closing balance Tax losses 1,206 —  (711 ) 495 Defined benefit obligation 247 —  (247 ) —  Intangible assets 280 —  (280 ) —  Leases 4 —  (4 ) —  Total deferred tax assets 1,737 —  (1,242 ) 495 Intangible assets 25,504 —  (4,768 ) 20,736 Total deferred tax liabilities 25,504 —  (4,768 ) 20,736 30.4 Unrecognized deferred tax assets The Group did not capitalize deferred tax assets from carryforward tax losses located in companies of the Group for which the availability of future taxable profits is uncertain. The cumulated tax losses on which no deferred tax assets have been capitalized will expire as follows: TCHF 2023 2022 Within one year 2,951 7,833 Later than one year and not later than five years 102,014 70,009 More than five years 50,823 67,016 Total tax losses carry forward 155,788 144,858 The deferred tax assets not recognized as of December 31, 2023, amounted to CHF 24 million (2022: CHF 22 million).

Share-based payments

Share-based payments	12 Months Ended
	Dec. 31, 2023
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Share-based payments	31. Share-based payments The Company maintains a stock option plan established in 2021 (the Stock Option Plan 2021), as well as a legacy stock option plan (the Equity Awards Program 2015) for which options remain outstanding. Stock option plans were established for the Company’s employees, directors, and consultants whereby each option gives its holder the right to purchase one share of the Company at a pre-determined As of December 31, 2023, the Company had 126,032 stock options outstanding. In addition, the Company committed to granting 320,000 options (exercise price: CHF 2.00) contingent upon the Company meeting certain technical requirements, including the availability of conditional capital and a reduction in the nominal value of the Company’s share capital. For expense recognition purposes, this contingent issuance was recognized as though it had been executed. The following table reconciles the stock options outstanding at the beginning and end of the year: 2023 2022 At beginning of the year 185,908 171,627 Granted 20,184 30,250 Exercised (4,871 ) (7,500 ) Forfeited (75,189 ) (8,469 ) At end of the year 126,032 185,908 Weighted average exercise price of granted options, in CHF 8.21 16.04 Weighted average exercise price of exercised options, in CHF 4.00 8.00 Weighted average exercise price of outstanding options, in CHF 22.43 22.98 In 2023, 75,189 options were forfeited, primarily due to the termination of certain employment contracts. Stock options outstanding at the end of the reporting period had the following expiry dates: Expiration year December 31, 2023 December 31, 2022 2023 —  250 2024 26,374 250 2025 250 250 2026 18,491 18,491 2027 24,084 53,917 2028 28,333 55,667 2029 24,250 47,833 2030 4,250 9,250 126,032 185,908 Exercisable 92,866 69,541 Weighted average remaining contractual life, in months 43 69 Stock options outstanding at the end of the reporting period had the following exercise prices: Exercise price December 31, 2023 December 31, 2022 From CHF 4.00 to CHF 5.00 56,158 63,658 From CHF 5.01 to CHF 10.00 7,500 37,500 From CHF 10.01 to CHF 20.00 16,292 35,250 Above CHF 20.00 46,082 49,500 126,032 185,908 The fair values of issued options and committed options were assessed using the Black-Scholes valuation model at the grant date and recognized over their vesting period. The weighted average fair value of options granted in 2023 was CHF 1.04. Significant inputs factored in valuation models for the options granted in 2023 were the share price at grant date (ranging from CHF 1.87 to CHF 9.20), the exercise price (ranging from CHF 2.00 to CHF 9.20), the volatility of returns (ranging from 66% to 69%), and the risk-free interest rate (ranging from 1.06% to 1.23%). The expected volatility assumes that historical volatility over a period similar to the life of the options is indicative of future trends, which may not necessarily be the actual outcome. The expected life of the options was estimated based on historical data by the Group, or when insufficient data was available, based on management’s estimates. In 2022, the weighted average fair value of options granted was CHF 8.00. Significant inputs were the share price at grant date (ranging from CHF 10.80 to CHF 24.00), the exercise price (ranging from CHF 10.80 to CHF 24.00), the volatility of returns (ranging from 71% to 80%), and the risk-free interest rate (ranging from 0% to 1%). In 2023, share-based payments of TCHF 814 (2022: TCHF 2,186) were recorded in personnel expenses with a corresponding credit to the share-based payment equity reserve (note 15).

Earnings per share

Earnings per share	12 Months Ended
	Dec. 31, 2023
Earnings per share [abstract]
Earnings per share	32. Earnings per share 2023 2022 Loss attributable to shareholders (in TCHF) (98,181 ) (50,790 ) Weighted average number of shares 11,752,466 10,570,281 Total basic and diluted loss per share (in CHF) (8.354 ) (4.805 ) Basic and diluted result per share is calculated by dividing the net result attributable to the shareholders of the Group’s parent company by the weighted average of shares outstanding during the year. In 2023 and 2022, the number of shares outstanding varied as a result of different transactions on the share capital structure of the Company. References to shares and per share amounts for the comparative period have been restated to reflect the reverse stock split (note 14). Neither outstanding options and warrants nor effects from the contingent liabilities payable in shares have been considered in the diluted loss calculation as their effect is anti-dilutive.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2023
Disclosure of detailed information about financial instruments [abstract]
Financial Instruments	33. Financial instruments 33.1. Categories of financial instruments December 31, 2023 TCHF Financial assets at amortised cost Financial liabilities at amortised cost Financial liabilities Total Other non-current 116 —  —  116 Trade receivables 1,171 —  —  1,171 Other current assets and receivables 1,740 —  —  1,740 Cash and cash equivalents 14,556 —  —  14,556 Total financial assets 17,583 —  —  17,583 Non-current —  2,086 —  2,086 Non-current —  9 —  9 Current lease liabilities —  524 —  524 Current borrowings —  337 —  337 Provisions for milestone payments —  —  6,203 6,203 Trade payables —  1,025 —  1,025 Financial liabilities due to related parties —  1,355 —  1,355 Other current payables and liabilities —  2,220 —  2,220 Total financial liabilities —  7,556 6,203 13,759 December 31, 2022 TCHF Financial assets at amortised cost Financial liabilities at amortised cost Financial liabilities at FVTPL Total Other non-current 114 —  —  114 Trade receivables 1,321 —  —  1,321 Other current assets and receivables 956 —  —  956 Cash and cash equivalents 19,237 —  —  19,237 Total financial assets 21,628 —  —  21,628 Non-current —  2,232 —  2,232 Non-current —  16 —  16 Current lease liabilities —  444 —  444 Current borrowings —  372 —  372 Provisions for milestone payments —  —  10,867 10,867 Trade payables —  1,625 —  1,625 Financial liabilities due to related parties —  1,280 —  1,280 Other current payables and liabilities —  2,214 —  2,214 Total financial liabilities —  8,183 10,867 19,050 33.2 Reconciliation of liabilities arising from financing activities Non cash-changes 2023 TCHF Opening Financing cash flows Additional Accrued Foreign Closing Lease liabilities (note 8.2) 2,676 (530 ) 420 —  44 2,610 Borrowings (note 16) 388 (20 ) —  —  (22 ) 346 Due to related parties (note 19) 1,280 —  —  75 —  1,355 Total 4,344 (550 ) 420 75 22 4,311 Non cash-changes 2022 TCHF Opening Financing cash flows Additional Accrued Foreign Closing Lease liabilities (note 8.2) 2,523 (390 ) 551 —  (8 ) 2,676 Borrowings (note 16) 491 (81 ) —  1 (23 ) 388 Due to related parties (note 19) 1,250 —  —  30 —  1,280 Total 4,264 (471 ) 551 31 (31 ) 4,344 33.3 Fair value measurement Financial liabilities at fair value through profit and loss (FVTPL) consist of contingent considerations resulting from business combinations. Further details on the fair value measurement of these liabilities are provided in note 18. 33.4 Amortized cost measurement For all other financial assets and liabilities, their carrying amount at amortized cost approximates their fair value.

Financial risk management

Financial risk management	12 Months Ended
	Dec. 31, 2023
Disclosure of detailed information about financial instruments [abstract]
Financial risk management	34. Financial risk management The Group is exposed to various financial risks, including credit risk, capital and liquidity risk, interest rate risk and currency risk. The following sections provide an overview of each of these risks, as well as the objectives, principles, and processes that the Group employs to mitigate them. Credit risk Credit risk refers to the risk that a counterparty will default on its contractual obligations towards the Group, resulting in financial loss to the Group. For product sales and trade account receivables, Relief may conduct selective analyses of the creditworthiness of distributors and other customers. Other financial assets mainly consist of cash for which the counterparty risk is minimized by deposits at well-known banks in Switzerland with an A rating as per Standard & Poor’s so that any expected credit loss is considered immaterial. In addition, the Group diversifies its exposure to banking risk by maintaining banking relationships with several institutions. The carrying amounts of financial assets recorded in the financial statements represent the Group’s maximum exposure to credit risk without taking into account the value of any collateral obtained. Capital and liquidity risk The Group’s objectives when managing capital are to safeguard its ability to fund development and marketing activities in order to provide returns for shareholders and benefits for other stakeholders. The funds raised in various private financing rounds and other share placements executed since the listing of the Company have been the principal source of liquidity, to date. Liquidity risk management implies maintaining sufficient cash and cash equivalents to meet the financial obligations of the Group. The management monitors the Group’s net liquidity position through rolling forecasts of cash flows. Maintaining adequate capital and cash reserves is dependent on the Group’s ability to raise funds or generate profits; therefore, capital and liquidity risks are significant (see note 4.1 ‘going concern’). Interest rate risk The Group is exposed to interest risk with respect to its cash deposits, bank loans and other interest-bearing liabilities. The Group deems the interest rate risk as low on its performance and its equity. Currency risk The Group operates internationally and is exposed to currency risk arising from various exposures, primarily with respect to the Swiss franc, Euro and US dollar. Currency risk arises from future transactions, recognized assets and liabilities and net investments in foreign operations. To manage such risk, the Group monitors its exposure by periodically assessing future spending needs in foreign currencies and maintains foreign currency cash balances to cover anticipated requirements in the next six to twelve months. The Group did not enter into any forward currency transactions and did not hold any derivative currency contracts at the end of the reporting period. While the Group considers its current exposure to foreign currency risk to be low, adverse changes in the value of the Swiss franc could still have a significant negative impact on the Group’s financial condition, results of operations, and future prospects. Based on the 2023 Group’s operational transactions denominated in foreign currencies, and with all other variables held constant, a 5% variation in USD and EUR exchange rates against the Swiss franc would have resulted in a TCHF 384 impact on the Group’s 2023 result (2022: TCHF 251).

Related party transactions

Related party transactions	12 Months Ended
	Dec. 31, 2023
Disclosure of transactions between related parties [abstract]
Related party transactions	35. Related party transactions 35.1 Related party transactions With members of the Board of Directors and of the Executive Committee: TCHF 2023 2022 Short-term employee benefits 2,267 2,873 Post-employment benefits 90 89 Other benefits 452 —  Share-based compensation 246 —  Total compensation 3,055 2,962 Further details on management’s compensation are provided in the compensation report. 35.2 Related party balances As of December 31, 2023, the liability of TCHF 1,355 due to GEM (December 31, 2022: TCHF 1,280) was the only material related party balance.

Non-cash transactions

Non-cash transactions	12 Months Ended
	Dec. 31, 2023
Non Cash Transactions [Abstract]
Non-cash transactions	36. Non-cash In 2023, the Group engaged in non-cash In 2022, these transactions included the execution of new leasing contracts for equipment (note 8), as well as the issuance of a TCHF 4,200 share payment in October 2022 following the completion of a milestone related to the APR acquisition.

Contingent liabilities

Contingent liabilities	12 Months Ended
	Dec. 31, 2023
Disclosure of contingent liabilities [abstract]
Contingent liabilities	37. Contingent liabilities 37.1 Business combinations with APR and AdVita The acquisition agreements for APR and AdVita provide for remaining contingent payment obligations in the aggregate maximum amounts of CHF 28 million and EUR 10 million (CHF 9.3 million), respectively, payable upon achievement of pre-agreed 37.2 Acquisition of RLF-OD32 Pursuant to the agreement concluded with Meta Healthcare Ltd. for the acquisition of RLF-OD32 pre-specified RLF-OD32 37.3 License agreement with Acer (note 7.2) Pursuant to the license agreement concluded with Acer in August 2023, Relief shall pay Acer a variable, continuing royalty up to a maximum of 10% of potential future net sales of OLPRUVA ® ® 37.4 Settlement agreement with NRx Pharmaceuticals Pursuant to the settlement and asset purchase agreements concluded with NRx Pharmaceuticals, Inc. (“NRx”) in November 2022, Relief committed to pay NRx up to USD 13 million (CHF 10.9 million) in aggregate as milestone payments upon marketing approval of an Aviptadil product. Additionally, Relief has agreed to pay single-digit percentage royalties on possible future sales of an Aviptadil product, up to a maximum of USD 30 million (CHF 25.2 million) in aggregate.

Events After The Reporting Peri

Events After The Reporting Period	12 Months Ended
	Dec. 31, 2023
Disclosure of non-adjusting events after reporting period [abstract]
Events after the reporting period	38. Events after the reporting period 38.1 Renewal of the Share Subscription Facility with GEM, debt waiver, and issuance of warrants In February 2024, the Company renewed the SSF agreement with GEM for an additional three-year period ending January 20, 2027. GEM also agreed to forgive an outstanding liability of TCHF 1,368. In consideration of GEM’s capital commitment and this debt waiver, Relief committed to issuing GEM warrants to purchase up to 3.35 million ordinary shares at a purchase price of CHF 1.70 per share, exercisable from the issuance date, and expiring on January 20, 2027. The issuance of these warrants was contingent upon shareholder approval for a reduction in the nominal value of the Company’s ordinary shares, which materialized in April 2024. Further information about the SSF agreement and GEM’s outstanding liability is in note 19. 38.2 License and Supply Agreement with Eton Pharmaceuticals, Inc. On March 21, 2024, the Company entered into a license and supply agreement g ran ® mid-teens 38.3 Subsequent changes to the capital structure On April 26, 2024, the extraordinary general meeting of the Company’s shareholders approved a reduction of the nominal value of each ordinary share from CHF 4.00 to CHF 0.10, an increase of the capital band to 7,000,000 shares, and an increase of the conditional capital to 7,000,000 shares. There were no other material events after the balance sheet date that would require adjustment to these consolidated financial statements or disclosure under this heading.

Summary of material accountin_2

Summary of material accounting policies (Policies)	12 Months Ended
	Dec. 31, 2023
Disclosure Of Material Accounting Policies [Abstract]
Basis of preparation	3.1 Basis of preparation The consolidated financial statements of the Group have been prepared in accordance with the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB) and comply with Swiss law. They have been prepared under the historical cost convention, as modified by the revaluation of financial instruments at fair value, and are presented in Swiss francs (CHF). All values are rounded to the nearest thousand (TCHF), except when otherwise indicated.
Reclassification	3.2 Reclassification A gain of TCHF 8,892 on fair value remeasurement of contingent consideration in the comparative period of the consolidated statement of comprehensive loss has been reclassified from ‘Other gains’ to a distinct line ‘Change in fair value of contingent consideration’ to conform with the current period presentation. This line item has been classified below EBITDA to enhance the presentation and understandability of the Company’s consolidated statement of comprehensive loss. Gains or losses from changes in the fair value of contingent considerations (note 18) are non-cash This reclassification had no impact on the Group’s previously reported financial positions or net loss for the period.
Basis of consolidation	3.3 Basis of consolidation The consolidated financial statements comprise the financial statements of the parent company RELIEF THERAPEUTICS Holding SA and its subsidiaries as of December 31, 2023 and 2022. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Specifically, the Group controls an investee if and only if the Group has: • power over the investee (i.e., existing rights that give it the current ability to direct the relevant activities of the investee); • exposure, or rights, to variable returns from its involvement with the investee; and • the ability to use its power over the investee to affect its returns. When the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including: • any contractual arrangement with the other vote holders of the investee; • rights arising from other contractual arrangements; and • the Group’s voting rights and potential voting rights. The Group reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the year are included in the statement of comprehensive income from the date the Group gains control until the date the Group ceases to control the subsidiary.
Current versus non-current classification	3.4 Current versus non-current The Group presents assets and liabilities in its statement of financial position based on current/non-current • expected to be realized or intended to be sold or consumed in a normal operating cycle, which is twelve months; • held primarily for the purpose of trading; • expected to be realized within twelve months after the reporting period; or • cash or cash equivalents unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. All other assets are classified as non-current. A liability is current when: • it is expected to be settled in a normal operating cycle, which is twelve months; • it is held primarily for the purpose of trading; • it is due to be settled within twelve months after the reporting period; or • there is no unconditional right to defer the settlement of the liability within twelve months after the reporting period. The Group classifies all other liabilities as non-current. Deferred tax assets and liabilities are classified as non-current
Business combinations and goodwill	3.5 Business combinations and goodwill Business combinations are accounted for using the acquisition method. The cost of an acquisition is measured as the aggregate of the consideration transferred measured at acquisition date fair value and the amount of any non-controlling non-controlling When the Group acquires a business, it assesses the financial assets and liabilities assumed for appropriate classification and designation in accordance with the contractual terms, economic circumstances and pertinent conditions as of the acquisition date. This includes the separation of embedded derivatives in host contracts by the acquiree. If the business combination is achieved in stages, any previously held equity interest is re-measured Any contingent consideration to be transferred by the acquirer will be recognized at fair value at the acquisition date. Contingent consideration classified as an asset or liability that is a financial instrument and within the scope of IFRS 9, is measured at fair value with changes in fair value recognized in profit or loss. If the contingent consideration is not within the scope of IFRS 9, it is measured in accordance with the applicable IFRS. Contingent consideration that is classified as equity, if any, is not re-measured Goodwill is initially measured at cost, being the excess of the aggregate of the consideration transferred and the amount recognized for non-controlling re-assesses After initial recognition, goodwill is measured at cost less any accumulated impairment losses. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to the Group’s cash-generating units that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units. Where goodwill has been allocated to a cash-generating unit and part of the operation within that unit is disposed of, the goodwill associated with the disposed operation is included in the carrying amount of the operation when determining the gain or loss on disposal. Goodwill disposed in these circumstances is measured based on the relative values of the disposed operation and the portion of the cash-generating unit retained.
Revenue recognition	3.6 Revenue recognition Relief may generate revenues from collaboration and license agreements under which Relief grants licenses to use, research, develop, manufacture and commercialize product candidates and products. Relief determined that those collaboration and license agreements qualify as contracts with its customers. If the grant of a license is bundled together with the rendering of services, it is assessed whether these agreements are comprised of more than one performance obligation. A performance obligation is only accounted for as the grant of a license if the grant of a license is the sole or the predominant promise of the performance obligation. If the consideration in an agreement includes a variable amount, Relief estimates the amount of consideration to which Relief will be entitled in exchange for transferring the goods to the customer. At contract inception, the variable consideration is estimated based on the most likely amount of consideration expected from the transaction and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with respect to the variable consideration is subsequently resolved. The estimated revenue is updated at each reporting date to reflect the current facts and circumstances. If a contract with a customer contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative stand-alone selling prices. For each separate performance obligation, it is evaluated whether control is transferred either at a point in time or over time. For performance obligations that are satisfied over time, revenue is recognized based on a measure of progress, which depicts the performance in transferring control to the customer. If under the terms of its licensing arrangements Relief provides the licensee with a research and development license, which represents a right to access Relief’s intellectual property as it exists throughout the license period, the promise to grant a license is accounted for as a performance obligation satisfied over time, as the licensee simultaneously receives and consumes the benefits of Relief’s performance. Earnings based on the collaboration partners’ gross profit, which is shared under the respective collaboration agreements, are recognized when the underlying sales occur, which is when the performance obligation has been satisfied. Relief uses certain information from its collaboration partners, some of which is based on preliminary data shared between the partners and might vary once final data is available. Revenue arrangements that involve two or more partners who contribute to the provision of a specific good or service to a customer are assessed in terms of principal-agent considerations in order to determine the appropriate treatment for the transactions between Relief, partners, and third parties. The classification of transactions under such arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which Relief is considered the principal, which includes being in control of the good or service before such good or service is transferred to the customer, is accounted for as gross revenue. Any consideration related to activities in which Relief is considered the agent, is accounted for as net revenue. Revenue from the sale of products is recognized when Relief transfers control of the product to the customer. Control of the product normally transfers when the customer gains physical possession and Relief has not retained any significant risks of ownership or future obligations with respect to the product. A receivable is recognized, as the consideration is unconditional and only the passage of time is required before payment is due. The transaction price is quoted in the relevant price lists in force at the date of the customer placing the respective order for such products. Revenue from research and development services provided by the Company is recorded as earned based on the performance requirements of the underlying contracts. Where agreements include milestones that are determined to be substantive and at risk at the inception of the agreement, revenue is recognized upon confirmation by the counterparty that the milestone has been achieved.
Foreign currency translation	3.7 Foreign currency translation Functional and presentation currency Items included in the financial statements of each of the Group’s entities are measured using the currency of the primary economic environment in which the entity operates (i.e., the functional currency). The consolidated financial statements are presented in CHF, which is the presentation currency of the Group. Transactions and balances In preparing the financial statements of each group entity, transactions in currencies other than the entity’s functional currency are recognized at the rates of exchange prevailing at the dates of the transactions. At the end of each reporting period, monetary items denominated in foreign currencies are re-translated Non-monetary re-translated. Group companies Assets and liabilities of Group entities using a functional currency different from the presentation currency are translated into the presentation currency using year-end
Intangible assets	3.8 Intangible assets Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and impairment losses. Internally generated intangibles, excluding capitalized development costs, are not capitalized and the related expenditure is reflected in profit or loss in the period in which the expenditure is incurred. The useful lives of intangible assets are assessed as either finite or indefinite. Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortization period or method, as appropriate, and are treated as changes in accounting estimates. Amortization of capitalized in process research & development (IPR&D) starts once the asset is available for use, which is usually the point in time at which marketing approval is granted by the relevant authority. Before that date, capitalized IPR&D that is not available for use is tested at least annually for impairment, irrespective of whether any indication of impairment exists. Gains or losses arising from the de-recognition
Leases	3.9 Leases The Group assesses whether a contract is or contains a lease at the inception of the contract. The Group recognizes a right-of-use The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the Group uses its incremental borrowing rate for such liabilities. Lease payments included in the measurement of the lease liability comprise: • fixed lease payments (including in-substance • variable lease payments that depend on an index or rate, initially measured using the index or rate at the commencement date; • the amount expected to be payable by the lessee under residual value guarantees; • the exercise price of purchase options, if the lessee is reasonably certain to exercise the options; and • payments of penalties for terminating the lease if the lease term reflects the exercise of an option to terminate. The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using the effective interest method) and by reducing the carrying amount to reflect the lease payments made. The right-of-use Right-of right-of-use right-of-use The Group has elected not to recognize right-of-use low-value
Financial assets	3.10 Financial assets Classification The Group has only financial assets classified within the categories “financial assets at fair value through profit or loss (FVTPL)” and “financial assets at amortized cost.” The classification at initial recognition depends on the financial asset’s contractual cash flow characteristics and the Group’s business model for managing them. The Group’s financial assets at amortized cost include other current assets and other receivables that are non-derivative Recognition and measurement Financial assets at amortized cost are measured initially at their fair value and are subsequently measured at amortized cost using the effective interest rate method and are subject to impairment. A financial asset is derecognized when: • the contractual rights to the cash flows from the asset have expired; or • the Group has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a pass-through arrangement; and either (a) the Group has transferred substantially all the risks and rewards of the asset, or (b) the Group has neither transferred nor retained substantially all the risks and rewards of the asset but has transferred control of the asset. Financial assets at FVTPL are measured at fair value at the end of each reporting period, with any fair value gains or losses recognized in profit or loss. Fair value is determined in the manner described in note 33. Impairment of financial assets The Group recognizes an allowance for expected credit losses (ECL) for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms. ECLs are recognized in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next twelve months (a twelve-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL). The Group considers a financial asset in default when contractual payments are 90 days
Inventories	3.11 Inventories Raw materials and merchandise purchased are recognized at cost; semi-finished and finished goods at their production cost. Discounts are recognized as a reduction in the purchase price. Manufacturing costs include the associated direct production costs and production overheads, where applicable. If the acquisition or manufacturing costs are higher than the net market value, an impairment loss is recorded on the income statement in the current period to write the inventories down to the net market value (lower of cost or market principle). Net market value is equivalent to the current market price less the usual sales deductions, marketing costs and administrative costs yet to be incurred. Inventories that cannot be sold are written off in full. The costs of inventories are determined by using the FIFO method. Inventory related to drug products that have not yet obtained regulatory approval is immediately written down to zero. The write-down is charged to research and development expenses. If regulatory approval is subsequently obtained, the recorded expenses are not reversed.
Cash and cash equivalents	3.12 Cash and cash equivalents Cash and cash equivalents include cash in hand, deposits held at call with banks and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts are shown within financial debts in current liabilities on the balance sheet. This definition is also used for the purposes of the cash flow statement.
Financial liabilities	3.13 Financial liabilities The Group’s financial liabilities include trade and other payables as well as borrowings. Financial liabilities are recognized initially at fair value and are subsequently measured at amortized cost using the effective interest rate method, with interest expense recognized on an effective yield basis. The Group derecognizes financial liabilities when, and only when, the Group’s obligations are discharged, canceled, or expired.
Current and deferred income tax	3.14 Current and deferred income tax The tax expense for the period comprises current and deferred tax. Tax is recognized in the income statement, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. In this case, the tax is also recognized in other comprehensive income or directly in equity, respectively. Deferred income tax is recognized, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, the deferred income tax is not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that, at the time of the transaction, affects neither accounting nor taxable profit or loss, and does not give rise to equal taxable and deductible temporary differences. Deferred income tax is determined using tax rates and applicable laws that have been enacted or substantively enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Deferred income tax is provided on temporary differences arising on investments in subsidiaries and associates, except for deferred income tax liability where the timing of the reversal of the temporary difference is controlled by the Group and it is probable that the temporary difference will not reverse in the foreseeable future.
Fair values	3.15 Fair values Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either: • in the principal market for the asset or liability, or • in the absence of a principal market, in the most advantageous market for the asset or liability. The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. The fair values of financial assets and liabilities at the balance sheet date are not materially different from their reported carrying values unless specifically mentioned in the notes to the consolidated financial statements.
Research and development costs	3.16 Research and development costs Research and development costs consist primarily of remuneration and other expenses related to research and development personnel, costs associated with preclinical testing and clinical trials of product candidates, expenses for research and development services under collaboration agreements and outsourced research and development expenses. Furthermore, the Group may acquire in-process In-process Internal development costs are capitalized as intangible assets only when there is an identifiable asset that can be completed and that will generate probable future economic benefits and when the cost of such an asset can be measured reliably.
Employee benefits	3.17 Employee benefits General Wages, salaries, social security contributions, paid annual leave and sick leave, bonuses, and non-monetary Pension obligations The cost of providing benefits under the defined benefit plan is determined using the projected unit credit method. Re-measurements, Re-measurements Past service costs are recognized in profit or loss on the earlier of: • the date of the plan amendment or curtailment, or • the date that the Group recognizes restructuring-related costs. Net interest is calculated by applying the discount rate to the net defined benefit liability or asset. The Group recognizes the following changes in the net defined benefit obligation under ‘personnel expense’ in the statement of comprehensive income: • service costs comprising current service costs, past-service costs, gains and losses on curtailments and non-routine • net interest expense or income. 3.18 Share-based payments The cost of equity-settled transactions is determined by the fair value at the date when the grant is made using an appropriate valuation model. That cost is recognized, together with a corresponding increase in other capital reserves in equity, over the period in which the performance and/or when service conditions are fulfilled as employee benefit expenses. The cumulative expense recognized for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Group’s best estimate of the number of equity instruments that will ultimately vest. The statement of profit or loss expense or credit for a period represents the movement in cumulative expense recognized at the beginning and end of that period and is recognized in employee benefits expense. No expense is recognized for awards that do not ultimately vest, except for equity-settled transactions for which vesting is conditional upon a market or non-vesting non-vesting When the terms of an equity-settled award are modified, the minimum expense recognized is the expense as if the terms had not been modified if the original terms of the award have been met. An additional expense is recognized for any modification that increases the total fair value of the share-based payment transaction or is otherwise beneficial to the employee as measured at the date of modification. The dilutive effect of outstanding options is reflected as additional share dilution in the computation of diluted earnings per share.

Group companies (Tables)

Group companies (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of subsidiaries [abstract]
Summary of Subsidiaries	The following table lists subsidiaries controlled by Relief at the end of the reporting period. Name Country Location Equity interest 2023 2022 Relief Therapeutics International SA Switzerland Geneva 100 % 100 % Relief Therapeutics US, Inc. United States Connecticut 100 % 100 % Relief Therapeutics, Inc. United States Delaware 100 % 100 % APR Applied Pharma Research SA Switzerland Balerna 100 % 100 % APR Applied Pharma Research Holding SA Switzerland Balerna 100 % 100 % APR Applied Pharma Research - Italy s.r.l. Italy Monza 100 % 100 % APR Applied Pharma Research Deutschland GmbH Germany Offenbach am Main 100 % 100 % AdVita Lifescience GmbH Germany Freiburg im Breisgau 100 % 100 % AdVita Lifescience AG Switzerland Basel 100 % 100 % AdVita Lifescience, Inc. United States New York 100 % 100 %

Segment information (Tables)

Segment information (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of operating segments [abstract]
Summary of Disaggregation of the Group's Revenue	The disaggregation of the Group’s revenue is presented in the following table. Revenue is reported by geographical location based on the location of the customer or licensee and, for R&D services, based on the location where the services were performed. TCHF 2023 2022 Revenue streams Royalties 1,411 2,482 Product sales 4,256 2,525 Licensing fees 19 380 Revenue from research and development services 347 694 Total revenue 6,033 6,081 Geographical area Switzerland 414 800 Europe (excluding Switzerland) 2,886 2,412 North America 1,406 1,699 Rest of the world 1,327 1,170 Total revenue 6,033 6,081 Timing of revenue recognition Point in time 6,033 6,081 Over time —  —  Total revenue 6,033 6,081
Summary of Geographical Location Non-current Assets	6.3 Geographical location of non-current TCHF December 31, 2023 December 31, 2022 Switzerland 57,189 165,484 Rest of the world 193 122 Total non-current 57,382 165,606 * Without financial assets and deferred tax assets

Intangible assets (Tables)

Intangible assets (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure Of Intangible Assets And Goodwill [Abstract]
Summary of Intangible Assets	TCHF Technologies, patents and Licenses In-process Goodwill Total Historical cost January 1, 2022 39,357 13,729 132,395 8,658 194,139 Addition 174 —  314 —  488 December 31, 2022 39,531 13,729 132,709 8,658 194,627 Acquisition price adjustment —  —  (188 ) —  (188 ) Divestment —  (9,747 ) —  (455 ) (10,202 ) December 31, 2023 39,531 3,982 132,521 8,203 184,237 Accumulated amortization and impairment January 1, 2022 (1,840 ) —  —  —  (1,840 ) Amortization (3,448 ) —  —  —  (3,448 ) Impairment (24,255 ) —  (529 ) (1,640 ) (26,424 ) December 31, 2022 (29,543 ) —  (529 ) (1,640 ) (31,712 ) Amortization (1,930 ) (752 ) —  —  (2,682 ) Impairment —  —  (89,878 ) (6,017 ) (95,895 ) Divestment —  466 —  —  466 December 31, 2023 (31,473 ) (286 ) (90,407 ) (7,657 ) (129,823 ) Carrying amount per class December 31, 2022 9,988 13,729 132,180 7,018 162,915 December 31, 2023 8,058 3,696 42,114 546 54,414 Carrying amount per asset PKU GOLIKE 4,344 —  —  —  4,344 Diclofenac 3,714 —  —  360 4,074 ACER-001 —  3,696 —  186 3,882 RLF-100 —  —  17,130 —  17,130 RLF-TD011 —  —  24,858 —  24,858 Sentinox —  —  —  —  —  RLF-OD032 —  —  126 —  126 December 31, 2023 8,058 3,696 42,114 546 54,414 PKU GOLIKE 4,678 —  —  —  4,678 Diclofenac 5,310 —  —  360 5,670 ACER-001 —  13,729 —  641 14,370 RLF-100 —  —  81,516 3,805 85,321 RLF-TD011 —  —  47,392 2,212 49,604 Sentinox —  —  2,958 —  2,958 RLF-OD032 —  —  314 —  314 December 31, 2022 9,988 13,729 132,180 7,018 162,915

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2023
Presentation of leases for lessee [abstract]
Summary of Right-of-use Assets	8.1 Right-of-use TCHF Building Equipment Total Historical cost January 1, 2022 2,538 139 2,677 Addition —  549 549 Foreign exchange difference (9 ) (2 ) (11 ) December 31, 2022 2,529 686 3,215 Addition 86 468 554 Disposal (89 ) (46 ) (135 ) Foreign exchange difference (6 ) (2 ) (8 ) December 31, 2023 2,520 1,106 3,626 Accumulated depreciation January 1, 2022 (147 ) (32 ) (179 ) Depreciation (292 ) (105 ) (397 ) Foreign exchange difference 3 —  3 December 31, 2022 (436 ) (137 ) (573 ) Depreciation (285 ) (252 ) (537 ) Disposal 41 11 52 Foreign exchange difference 1 1 2 December 31, 2023 (679 ) (377 ) (1,056 ) Carrying amount at December 31, 2022 2,093 549 2,642 at December 31, 2023 1,841 729 2,570
Summary of Maturity of Lease Liabilities	8.2 Maturity of lease liabilities TCHF December 31, 2023 December 31, 2022 < 1 year 524 444 1-5 1,824 1,455 > 5 years 262 777 Total 2,610 2,676
Summary of Amounts Recognized in Profit or Loss Related to Leases	8.3 Amounts recognized in profit or loss TCHF December 31, 2023 December 31, 2022 Lease expense for short-term and low value leases 54 182 Depreciation expense on right-of-use 537 392 Interest expense on lease liabilities (note 29) 27 33

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2023
Inventories [Abstract]
Summary of Inventories	TCHF December 31, 2023 December 31, 2022 Raw material 2,728 2,758 Finished goods 656 139 Gross inventories 3,384 2,897 Valuation allowance (2,827 ) (2,670 ) Total 557 227

Trade receivables (Tables)

Trade receivables (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of trade receivables [Abstract]
Summary of Current Trade Receivables	TCHF December 31, 2023 December 31, 2022 Current receivables 1,419 1,548 Expected credit loss allowance (248 ) (227 ) Total 1,171 1,321
Summary of Trade Receivables Expected Credit Loss Allowance	TCHF 2023 2022 Balance at beginning of year (227 ) (204 ) Impairment losses recognized (36 ) (23 ) Reversal of impairment losses 15 —  Balance at end of year (248 ) (227 )

Other current assets (Tables)

Other current assets (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure Of Other Current Assets [Abstract]
Summary of Information about Other Current Assets	TCHF December 31, 2023 December 31, 2022 Other receivable (note 7.2) 972 —  Accrued revenue 501 723 Prepaid expenses 345 836 VAT receivable 168 147 Deposits 9 28 Other current receivables 25 64 Total 2,020 1,798

Share capital (Tables)

Share capital (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of classes of share capital [abstract]
Summary of Share Capital	Number of shares Common shares Treasury shares Total Balance at January 1, 2022 11,033,337 (749,669 ) 10,283,668 Issuance of treasury shares 3,000,000 (3,000,000 ) —  Direct Share Placement program —  347,145 347,145 Milestone payments —  375,500 375,500 Exercises of options 7,500 —  7,500 Balance at December 31, 2022 14,040,837 (3,027,024 ) 11,013,813 Balance at January 1, 2023 14,040,837 (3,027,024 ) 11,013,813 Direct Share Placement program —  24,947 24,947 Private placements —  1,200,000 1,200,000 Exercise of pre-funded —  300,000 300,000 Withdrawal of fractional shares —  (3,009 ) (3,009 ) Exercises of options —  4,688 4,688 Balance at December 31, 2023 14,040,837 (1,500,398 ) 12,540,439

Reserves (Tables)

Reserves (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of reserves within equity [abstract]
Summary of reserves	TCHF December 31, 2023 December 31, 2022 Share premium (note 15.1) 214,180 215,688 Share-based payment reserve (note 15.2) 5,371 4,557 Foreign currency translation reserve (note 15.3) 779 716 Total 220,330 220,961 15.1 Share premium TCHF 2023 2022 Balance at beginning of year 215,688 207,521 Net paid-in (1,014 ) 8,390 Transaction cost in relation to capital increases (494 ) (223 ) Balance at end of year 214,180 215,688 15.2 Share-based payment reserve TCHF 2023 2022 Balance at beginning of year 4,557 2,371 Share-based payments (note 31) 814 2,186 Balance at end of year 5,371 4,557 15.3 Foreign currency translation reserve TCHF 2023 2022 Balance at beginning of year 716 255 Exchange differences arising on translating foreign operations 63 461 Balance at end of year 779 716

Defined benefit obligations (Ta

Defined benefit obligations (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of information about defined benefit plans [abstract]
Summary of Defined Benefit Plans	The following table provides information on the amounts recognized in the balance sheet: TCHF December 31, 2023 December 31, 2022 Present value of pension benefit obligation 4,517 4,044 Fair value of pension plan assets (3,532 ) (3,494 ) Net pension defined benefit obligation 985 550 Present value of other benefit obligations 604 1,222 Total defined benefit obligations 1,589 1,772
Summary of Amount Recognized In Profit Or Loss In Respect of Defined Benefit Plans	The amounts recognized in profit or loss for these defined benefit plans were as follows: TCHF 2023 2022 Net service cost 212 207 Net interest expense 7 4 Administration cost excl. cost for managing plan assets 31 23 Expense recognized in profit or loss 250 234
Summary of Amount Recognized In Other Comprehensive Income In Respect of Defined Benefit Plans	The amounts recognized in other comprehensive income for these defined benefit plans were as follows: TCHF 2023 2022 Remeasurement (gain)/loss on defined benefit obligation due to changes in demographic assumptions (11 ) —  due to changes in financial assumptions 426 (1,150 ) due to changes in experience adjustments (31 ) 156 Return on plan assets excl. interest income 100 52 Expense/(Income) recognized in other comprehensive income 484 (942 )
Summary of Movement In The Present Value of Defined Benefit Obligation	The movements in the present value of the defined benefit obligation were as follows: TCHF 2023 2022 Opening defined benefit obligation 4,044 4,496 Net service cost 212 207 Interest expense on defined benefit obligation 85 13 Contributions from plan participants 129 129 Benefits (paid)/deposited (337 ) 193 Remeasurement (gain)/loss due to changes in demographic assumptions (11 ) —  Remeasurement (gain)/loss due to changes in financial assumptions 426 (1,150 ) Remeasurement (gain)/loss due to changes in experience adjustments (31 ) 156 Closing defined benefit obligation 4,517 4,044
Summary of Movement In The Present Value of Defined Benefit Plan Assets	Movements in the present value of the plan assets in the current period were as follows: TCHF 2023 2022 Opening fair value of plan assets 3,494 2,946 Interest income on plan assets 78 9 Return on plan assets excluding interest income (100 ) (52 ) Contributions from the employer 299 292 Contributions from plan participants 129 129 Benefits (paid)/deposited (337 ) 193 Administration cost (31 ) (23 ) Closing fair value of plan assets 3,532 3,494
Summary of Detailed Information About Principal Actuarial Assumptions	Principal assumptions used for the purposes of the actuarial valuations were as follows: TCHF 2023 2022 Discount rate          1.40 %       2.15 % Expected rate of salary increase 1.90 % 1.50 %

Provisions (Tables)

Provisions (Tables)	12 Months Ended
	Dec. 31, 2023
Provisions [abstract]
Summary of Provisions	TCHF Contingent consideration (i) Legal and regulatory (ii) Other (iii) Total Balance at December 31, 2022 10,867 136 —  11,003 Addition —  —  235 235 Unwinding of discount on provisions 303 —  —  303 Variation due to assumption adjustment (4,782 ) —  —  (4,782 ) Foreign exchange difference (185 ) —  —  (185 ) Utilization —  (136 ) —  (136 ) Balance at December 31, 2023 6,203 —  235 6,438 thereof current —  —  235 235 thereof non-current 6,203 —  —  6,203

Other current payables and li_2

Other current payables and liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of other current payables and liabilities [Abstract]
Summary of other current payables and liabilities	TCHF December 31, 2023 December 31, 2022 Accrued expenses 1,736 2,138 Personnel-related accruals and payables 1,049 497 Stamp duty and capital tax liabilities 51 347 Deferred revenue 114 776 Other current liabilities 483 143 Total 3,433 3,901

Other gains (Tables)

Other gains (Tables)	12 Months Ended
	Dec. 31, 2023
Expenses by nature [abstract]
Summary of Other Gains	TCHF 2023 2022 Divestment gain (note 7.2) 125 —  Income from sublease agreements 99 94 Reversal of impairment on financial assets —  453 Reversal of impairment on other receivables 58 235 Various others 13 247 Total other gains 295 1,029

Personnel expenses (Tables)

Personnel expenses (Tables)	12 Months Ended
	Dec. 31, 2023
Classes of employee benefits expense [abstract]
Personnel expenses	TCHF 2023 2022 Salaries and social security expense 11,088 10,513 Independent contractors fees —  320 Share-based payment expense (note 31) 814 2,186 Service cost for other benefit obligations (64 ) (21 ) Total personnel expenses 11,838 12,998

Other administrative expenses (

Other administrative expenses (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure Of Administrative Expenses [Abstract]
Summary Of Information About Other Administrative Expenses	TCHF 2023 2022 Professional services 2,918 6,053 Other administrative expenses 2,473 1,694 Total other administrative expenses 5,391 7,747

Impairment expense (Tables)

Impairment expense (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure Of Impairment Expenses [Abstract]
Summary of Impairment expense	TCHF 2023 2022 Impairment losses on intangible assets (note 7) 95,895 26,424 Impairment losses on inventories (note 10) 184 —  Total impairment expense 96,079 26,424

Amortization and depreciation_2

Amortization and depreciation expense (Tables)	12 Months Ended
	Dec. 31, 2023
Depreciation and amortisation expense [abstract]
Summary of Amortisation And Depreciation Expense	TCHF 2023 2022 Amortization of intangible assets (note 7) 2,682 3,448 Depreciation of rights-of-use 537 392 Depreciation of property and equipment (note 9) 99 20 Total amortization and depreciation expense 3,318 3,860

Financial income and expenses (

Financial income and expenses (Tables)	12 Months Ended
	Dec. 31, 2023
DisclosureOfFinanceIncomeExpense [Abstract]
Summary of Financial Income and Expenses	TCHF 2023 2022 Interest income on cash deposits 64 —  Interest income on deferred payment (note 7.2) 29 —  Interest income on loans —  18 Total financial income 93 18 Unwinding of discount on provisions (note 18) (303 ) (1,308 ) SSF commitment fee (note 19) (417 ) (416 ) Negative interest on cash deposits —  (93 ) Interest expense related to leases (note 8) (27 ) (33 ) Bank charges (20 ) (40 ) Foreign exchange loss, net (65 ) (374 ) Other financial expenses (117 ) (30 ) Total financial expense (949 ) (2,294 )

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure Of Income Tax [Abstract]
Summary of Income Tax Recognized In Profit or Loss	30.1 Income tax recognized in profit or loss TCHF 2023 2022 Current tax Current tax expense for the year —  —  Adjustments in current tax of prior years —  —  —  —  Deferred tax Deferred tax income for the year (13,503 ) (4,977 ) Write-down of deferred tax assets —  1,451 (13,503 ) (3,526 ) Net income tax gain (13,503 ) (3,526 )
Summary of Detailed Information About Reconciliation of Effective and Applicable Income Tax Expenses	The following table provides a reconciliation between the income tax gain recognized for the year and the tax calculated by applying the applicable tax rates on the net result before income taxes. TCHF 2023 2022 Loss before tax (111,684 ) (54,316 ) Income tax expense calculated at 13.99% (2022: 13.99%) (15,625 ) (7,599 ) Unrecognized deferred tax assets during the year 2,138 4,235 Write-down of deferred tax assets —  1,451 Effect of deferred tax balances due to difference in applicable tax rates 24 (802 ) Effect of net (income)/expense that is not added/(deductible) (40 ) (811 ) Income tax recognized in the current year (13,503 ) (3,526 )
Summary of Temporary Difference, Unused Tax Losses And Unused Tax Credits	The following table sets out the changes in deferred tax assets and liabilities: 2023 TCHF Opening balance Recognized in OCI Recognized in profit or loss Closing balance Tax losses 495 —  94 589 Total deferred tax assets 495 —  94 589 Intangible assets 20,736 —  (13,370 ) 7,366 Total deferred tax liabilities 20,736 —  (13,370 ) 7,366 2022 TCHF Opening balance Recognized in OCI Recognized in profit or loss Closing balance Tax losses 1,206 —  (711 ) 495 Defined benefit obligation 247 —  (247 ) —  Intangible assets 280 —  (280 ) —  Leases 4 —  (4 ) —  Total deferred tax assets 1,737 —  (1,242 ) 495 Intangible assets 25,504 —  (4,768 ) 20,736 Total deferred tax liabilities 25,504 —  (4,768 ) 20,736
Summary of Detailed Information About Unrecognized Deferred Tax Assets	The Group did not capitalize deferred tax assets from carryforward tax losses located in companies of the Group for which the availability of future taxable profits is uncertain. The cumulated tax losses on which no deferred tax assets have been capitalized will expire as follows: TCHF 2023 2022 Within one year 2,951 7,833 Later than one year and not later than five years 102,014 70,009 More than five years 50,823 67,016 Total tax losses carry forward 155,788 144,858

Share-based payments (Tables)

Share-based payments (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Summary of Stock Options Outstanding	The following table reconciles the stock options outstanding at the beginning and end of the year: 2023 2022 At beginning of the year 185,908 171,627 Granted 20,184 30,250 Exercised (4,871 ) (7,500 ) Forfeited (75,189 ) (8,469 ) At end of the year 126,032 185,908 Weighted average exercise price of granted options, in CHF 8.21 16.04 Weighted average exercise price of exercised options, in CHF 4.00 8.00 Weighted average exercise price of outstanding options, in CHF 22.43 22.98
Summary of Share Options Outstanding	Stock options outstanding at the end of the reporting period had the following expiry dates: Expiration year December 31, 2023 December 31, 2022 2023 —  250 2024 26,374 250 2025 250 250 2026 18,491 18,491 2027 24,084 53,917 2028 28,333 55,667 2029 24,250 47,833 2030 4,250 9,250 126,032 185,908 Exercisable 92,866 69,541 Weighted average remaining contractual life, in months 43 69
Summary of Share Options Outstanding Exercise Prices	Stock options outstanding at the end of the reporting period had the following exercise prices: Exercise price December 31, 2023 December 31, 2022 From CHF 4.00 to CHF 5.00 56,158 63,658 From CHF 5.01 to CHF 10.00 7,500 37,500 From CHF 10.01 to CHF 20.00 16,292 35,250 Above CHF 20.00 46,082 49,500 126,032 185,908

Earnings per share (Tables)

Earnings per share (Tables)	12 Months Ended
	Dec. 31, 2023
Earnings per share [abstract]
Summary of Earnings Per Share	2023 2022 Loss attributable to shareholders (in TCHF) (98,181 ) (50,790 ) Weighted average number of shares 11,752,466 10,570,281 Total basic and diluted loss per share (in CHF) (8.354 ) (4.805 )

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of detailed information about financial instruments [abstract]
Summary of Categories of Financial Instruments	33.1. Categories of financial instruments December 31, 2023 TCHF Financial assets at amortised cost Financial liabilities at amortised cost Financial liabilities Total Other non-current 116 —  —  116 Trade receivables 1,171 —  —  1,171 Other current assets and receivables 1,740 —  —  1,740 Cash and cash equivalents 14,556 —  —  14,556 Total financial assets 17,583 —  —  17,583 Non-current —  2,086 —  2,086 Non-current —  9 —  9 Current lease liabilities —  524 —  524 Current borrowings —  337 —  337 Provisions for milestone payments —  —  6,203 6,203 Trade payables —  1,025 —  1,025 Financial liabilities due to related parties —  1,355 —  1,355 Other current payables and liabilities —  2,220 —  2,220 Total financial liabilities —  7,556 6,203 13,759 December 31, 2022 TCHF Financial assets at amortised cost Financial liabilities at amortised cost Financial liabilities at FVTPL Total Other non-current 114 —  —  114 Trade receivables 1,321 —  —  1,321 Other current assets and receivables 956 —  —  956 Cash and cash equivalents 19,237 —  —  19,237 Total financial assets 21,628 —  —  21,628 Non-current —  2,232 —  2,232 Non-current —  16 —  16 Current lease liabilities —  444 —  444 Current borrowings —  372 —  372 Provisions for milestone payments —  —  10,867 10,867 Trade payables —  1,625 —  1,625 Financial liabilities due to related parties —  1,280 —  1,280 Other current payables and liabilities —  2,214 —  2,214 Total financial liabilities —  8,183 10,867 19,050
Summary of Reconciliation of Liabilities Arising From Financing Activities	33.2 Reconciliation of liabilities arising from financing activities Non cash-changes 2023 TCHF Opening Financing cash flows Additional Accrued Foreign Closing Lease liabilities (note 8.2) 2,676 (530 ) 420 —  44 2,610 Borrowings (note 16) 388 (20 ) —  —  (22 ) 346 Due to related parties (note 19) 1,280 —  —  75 —  1,355 Total 4,344 (550 ) 420 75 22 4,311 Non cash-changes 2022 TCHF Opening Financing cash flows Additional Accrued Foreign Closing Lease liabilities (note 8.2) 2,523 (390 ) 551 —  (8 ) 2,676 Borrowings (note 16) 491 (81 ) —  1 (23 ) 388 Due to related parties (note 19) 1,250 —  —  30 —  1,280 Total 4,264 (471 ) 551 31 (31 ) 4,344

Related party transactions (Tab

Related party transactions (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of transactions between related parties [abstract]
Summary of With Members of the Board of Directors and of the Executive Committee	With members of the Board of Directors and of the Executive Committee: TCHF 2023 2022 Short-term employee benefits 2,267 2,873 Post-employment benefits 90 89 Other benefits 452 —  Share-based compensation 246 —  Total compensation 3,055 2,962

Summary of material accountin_3

Summary of material accounting policies - Additional Information (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Material Accounting Policies [Line Items]
Gain from fair value adjustments to contingent payments	SFr 4,782	SFr 8,892
Change in fair value of contingent consideration [member]
Disclosure Of Material Accounting Policies [Line Items]
Gain from fair value adjustments to contingent payments		SFr 8,892

Summary of critical accountin_2

Summary of critical accounting judgments and key sources of estimation uncertainty - Additional Information (Detail) SFr in Thousands, $ in Millions	1 Months Ended		12 Months Ended
	Aug. 31, 2023 CHF (SFr)	Aug. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2023 CHF (SFr)	Dec. 31, 2022 CHF (SFr)	Dec. 31, 2021 CHF (SFr)
Disclosure Of Critical Accounting Judgments And Key Sources Of Estimation Uncertainty [Line Items]
Cash and cash equivalents | SFr					SFr 14,556	SFr 19,237	SFr 44,761
Collaboration And License Agreement With Acer [member]
Disclosure Of Critical Accounting Judgments And Key Sources Of Estimation Uncertainty [Line Items]
Payment for acquisition of intangible assets				$ 15
Upfront payments expensed as development activity			$ 20	$ 20
New License Agreement [member]
Disclosure Of Critical Accounting Judgments And Key Sources Of Estimation Uncertainty [Line Items]
Percentage of entity's revenue	60%	60%
Percentage of royalty on net sales	10%	10%
Non-refundable payment received in exchange of commercialization	SFr 8,900	$ 10
Additional non-contingent payment receivable	SFr 1,300	$ 1.5

Group companies - Summary of su

Group companies - Summary of subsidiaries (Detail)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Relief Therapeutics International SA [member]
Disclosure of subsidiaries [line items]
Country	Switzerland
Location	Geneva
Equity interest	100%	100%
Relief Therapeutics US, Inc. [member]
Disclosure of subsidiaries [line items]
Country	United States
Location	Connecticut
Equity interest	100%	100%
Relief Therapeutics, Inc. [member]
Disclosure of subsidiaries [line items]
Country	United States
Location	Delaware
Equity interest	100%	100%
APR Applied Pharma Research SA [member]
Disclosure of subsidiaries [line items]
Country	Switzerland
Location	Balerna
Equity interest	100%	100%
APR Applied Pharma Research Holding SA [member]
Disclosure of subsidiaries [line items]
Country	Switzerland
Location	Balerna
Equity interest	100%	100%
APR Applied Pharma Research - Italy s.r.l. [member]
Disclosure of subsidiaries [line items]
Country	Italy
Location	Monza
Equity interest	100%	100%
APR Applied Pharma Research Deutschland GmbH [member]
Disclosure of subsidiaries [line items]
Country	Germany
Location	Offenbach am Main
Equity interest	100%	100%
AdVita Lifescience GmbH [member]
Disclosure of subsidiaries [line items]
Country	Germany
Location	Freiburg im Breisgau
Equity interest	100%	100%
AdVita Lifescience AG [member]
Disclosure of subsidiaries [line items]
Country	Switzerland
Location	Basel
Equity interest	100%	100%
AdVita Lifescience, Inc. [member]
Disclosure of subsidiaries [line items]
Country	United States
Location	New York
Equity interest	100%	100%

Segment Information - Additiona

Segment Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Customer 1 [member]
Disclosure of operating segments [line items]
Percentage of entity's revenue	12.50%	21.50%
Customer 2 [member]
Disclosure of operating segments [line items]
Percentage of entity's revenue	6.40%	16.20%
Customer 3 [member]
Disclosure of operating segments [line items]
Percentage of entity's revenue	6.10%	10.30%

Segment Information - Summary o

Segment Information - Summary of Disaggregation of the Group's Revenue (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue	SFr 6,033	SFr 6,081
Royalties [member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue	1,411	2,482
Product sales [member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue	4,256	2,525
Licensing fees [member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue	19	380
Revenue from research and development services [member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue	347	694
Switzerland [member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue	414	800
Europe (excluding Switzerland) [member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue	2,886	2,412
North America [member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue	1,406	1,699
Rest of the world [member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue	1,327	1,170
Point in time [member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue	6,033	6,081
Over time [member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue	SFr 0	SFr 0

Segment Information - Summary_2

Segment Information - Summary of Geographical Location Non-current Assets (Detail) - CHF (SFr) SFr in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure of geographical areas [line items]
Non-current assets	SFr 57,382	SFr 165,606
Switzerland [member]
Disclosure of geographical areas [line items]
Non-current assets	57,189	165,484
Rest of the world [member]
Disclosure of geographical areas [line items]
Non-current assets	SFr 193	SFr 122

Intangible assets - Summary of

Intangible assets - Summary of Intangible Assets (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	SFr 162,915
Amortization	2,682	SFr 3,448
Ending balance	54,414	162,915
PKU Golike [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	4,678
Ending balance	4,344	4,678
Diclofenac [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	5,670
Ending balance	4,074	5,670
ACER-001 [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	14,370
Addition	86
Ending balance	3,882	14,370
RLF-100 [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	85,321
Ending balance	17,130	85,321
RLF-TD011 [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	49,604
Ending balance	24,858	49,604
Sentinox [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	2,958
Ending balance	0	2,958
RLF-OD32 [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	314
Ending balance	126	314
Technologies, patents and trademarks [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	9,988
Impairment		(24,255)
Ending balance	8,058	9,988
Technologies, patents and trademarks [member] | PKU Golike [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	4,678
Ending balance	4,344	4,678
Technologies, patents and trademarks [member] | Diclofenac [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	5,310
Ending balance	3,714	5,310
Licences [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	13,729
Ending balance	3,696	13,729
Licences [member] | ACER-001 [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	13,729
Ending balance	3,696	13,729
In-process research and development [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	132,180
Ending balance	42,114	132,180
In-process research and development [member] | RLF-100 [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	81,516
Ending balance	17,130	81,516
In-process research and development [member] | RLF-TD011 [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	47,392
Ending balance	24,858	47,392
In-process research and development [member] | Sentinox [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	2,958
Ending balance	0	2,958
In-process research and development [member] | RLF-OD32 [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	314
Ending balance	126	314
Goodwill [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	7,018
Ending balance	546	7,018
Goodwill [member] | PKU Golike [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	0
Ending balance		0
Goodwill [member] | Diclofenac [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	360
Ending balance	360	360
Goodwill [member] | ACER-001 [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	641
Ending balance	186	641
Goodwill [member] | RLF-100 [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	3,805
Ending balance	0	3,805
Goodwill [member] | RLF-TD011 [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	2,212
Ending balance	0	2,212
Goodwill [member] | Sentinox [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	0
Ending balance		0
Gross Carrying Amount [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	194,627	194,139
Addition		488
Acquisition price adjustment		(188)
Divestment		(10,202)
Ending balance	184,237	194,627
Gross Carrying Amount [member] | Technologies, patents and trademarks [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	39,531	39,357
Addition		174
Ending balance	39,531	39,531
Gross Carrying Amount [member] | Licences [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	13,729	13,729
Addition		0
Divestment		(9,747)
Ending balance	3,982	13,729
Gross Carrying Amount [member] | In-process research and development [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	132,709	132,395
Addition		314
Acquisition price adjustment		(188)
Ending balance	132,521	132,709
Gross Carrying Amount [member] | Goodwill [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	8,658	8,658
Divestment		(455)
Ending balance	8,203	8,658
Accumulated amortization and impairment [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	(31,712)	(1,840)
Divestment	466
Amortization	(2,682)	(3,448)
Impairment	(95,895)	(26,424)
Ending balance	(129,823)	(31,712)
Accumulated amortization and impairment [member] | Technologies, patents and trademarks [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	(29,543)	(1,840)
Amortization	(1,930)	(3,448)
Impairment	0
Ending balance	(31,473)	(29,543)
Accumulated amortization and impairment [member] | Licences [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Divestment	466
Amortization	(752)
Ending balance	(286)
Accumulated amortization and impairment [member] | In-process research and development [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	(529)
Impairment	(89,878)	(529)
Ending balance	(90,407)	(529)
Accumulated amortization and impairment [member] | Goodwill [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning balance	(1,640)
Impairment	(6,017)	(1,640)
Ending balance	SFr (7,657)	SFr (1,640)

Intangible assets - Additional

Intangible assets - Additional Information (Detail) SFr in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2023 CHF (SFr)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 CHF (SFr)	Dec. 31, 2021 CHF (SFr)	Dec. 31, 2023 USD ($)
Disclosure of intangible assets and goodwill [line items]
Percentage of royalty on net sales payable	10%	10%
Discount rate applied to cash flow projections	15.41%		16.54%		15.41%
Impairment loss recognised in profit or loss, intangible assets other than goodwill	SFr 95,895		SFr 26,424
Intangible assets other than goodwill	SFr 54,414		SFr 162,915
Percentage of amount received on sub licensing	20%				20%
On Market Products [member]
Disclosure of intangible assets and goodwill [line items]
Explanation of period over which management has projected cash flows	five years	five years
Attrition rate	5%				5%
In Process Projects Products [member]
Disclosure of intangible assets and goodwill [line items]
Explanation of period over which management has projected cash flows	20 years	20 years
Acers Territories [member]
Disclosure of intangible assets and goodwill [line items]
Percentage of royalty on net sales payable	10%	10%
Percentage of amount received on licensing	20%				20%
Amount received on licensing	SFr 37,900	$ 45
ACER-001 [member]
Disclosure of intangible assets and goodwill [line items]
Additions other than through business combinations, intangible assets other than goodwill	SFr 86
Percentage of risk adjusted future economic benefits	71%				71%
Percentage of net carrying amount of the asset	71%				71%
Total non contingent consideration	SFr 10,200				$ 11.5
Disposals intangible assets and goodwill	1,300	$ 1.5
Disposals intangible assets other than goodwill	125
Expected credit loss provision amount	249
Sentinox [member]
Disclosure of intangible assets and goodwill [line items]
Impairment loss recognised in profit or loss, intangible assets other than goodwill	2,958
RLF-100 [member]
Disclosure of intangible assets and goodwill [line items]
Impairment loss recognised in profit or loss, intangible assets other than goodwill	64,386
CGU [Member]
Disclosure of intangible assets and goodwill [line items]
Impairment loss recognised in profit or loss, intangible assets other than goodwill	7,657
Acer [Member]
Disclosure of intangible assets and goodwill [line items]
Disposals intangible assets and goodwill	455
RLF TD 011 [Member]
Disclosure of intangible assets and goodwill [line items]
Impairment loss recognised in profit or loss, intangible assets other than goodwill	22,534
Generating Assets [Member]
Disclosure of intangible assets and goodwill [line items]
Intangible assets other than goodwill	SFr 6,017
Technologies, patents and trademarks [member]
Disclosure of intangible assets and goodwill [line items]
Weighted average amortization period of acquired intangible assets	8 years 6 months	8 years 6 months
Goodwill [member] | APR [member]
Disclosure of intangible assets and goodwill [line items]
Acquisition price adjustment				SFr 8,658
Bottom of range [member] | Technologies, patents and trademarks [member]
Disclosure of intangible assets and goodwill [line items]
Amortization period of acquired intangible assets	2 years	2 years
Bottom of range [member] | Intangible assets under development [member] | Probabilities of Success [member]
Disclosure of intangible assets and goodwill [line items]
Significant unobservable input, assets	12				12
Top of range [member] | Technologies, patents and trademarks [member]
Disclosure of intangible assets and goodwill [line items]
Amortization period of acquired intangible assets	13 years	13 years
Top of range [member] | Intangible assets under development [member] | Probabilities of Success [member]
Disclosure of intangible assets and goodwill [line items]
Significant unobservable input, assets	35				35

Leases - Summary of Right-of-us

Leases - Summary of Right-of-use Assets (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	SFr 2,642
Depreciation	537	SFr 392
Ending balance	2,570	2,642
Buildings [member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	2,093
Ending balance	1,841	2,093
Equipment [member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	549
Ending balance	729	549
Gross carrying amount [member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	3,215	2,677
Disposal	(135)
Addition	554	549
Foreign exchange difference	(8)	(11)
Ending balance	3,626	3,215
Gross carrying amount [member] | Buildings [member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	2,529	2,538
Disposal	(89)
Addition	86
Foreign exchange difference	(6)	(9)
Ending balance	2,520	2,529
Gross carrying amount [member] | Equipment [member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	686	139
Disposal	(46)
Addition	468	549
Foreign exchange difference	(2)	(2)
Ending balance	1,106	686
Accumulated depreciation and amortisation [member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	(573)	(179)
Disposal	52
Depreciation	(537)	(397)
Foreign exchange difference	2	3
Ending balance	(1,056)	(573)
Accumulated depreciation and amortisation [member] | Buildings [member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	(436)	(147)
Disposal	41
Depreciation	(285)	(292)
Foreign exchange difference	1	3
Ending balance	(679)	(436)
Accumulated depreciation and amortisation [member] | Equipment [member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	(137)	(32)
Disposal	11
Depreciation	(252)	(105)
Foreign exchange difference	1	0
Ending balance	SFr (377)	SFr (137)

Leases - Summary of Maturity of

Leases - Summary of Maturity of Lease Liabilities (Detail) - CHF (SFr) SFr in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Maturity Analysis For Lease Liabilities [Line Items]
Gross lease liabilities	SFr 2,610	SFr 2,676
Within one year [member]
Disclosure Of Maturity Analysis For Lease Liabilities [Line Items]
Gross lease liabilities	524	444
1-5 years [member]
Disclosure Of Maturity Analysis For Lease Liabilities [Line Items]
Gross lease liabilities	1,824	1,455
More than five years [member]
Disclosure Of Maturity Analysis For Lease Liabilities [Line Items]
Gross lease liabilities	SFr 262	SFr 777

Leases - Summary of Amounts Rec

Leases - Summary of Amounts Recognized in Profit or Loss Related to Leases (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Presentation of leases for lessee [abstract]
Lease expense for short-term and low value leases	SFr 54	SFr 182
Depreciation expense on right-of-use assets (note 28)	537	392
Interest expense on lease liabilities (note 29)	SFr 27	SFr 33

Leases - Additional Information

Leases - Additional Information (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Leases [Line Items]
Lease commitments for short-term leases for which recognition exemption has been used	SFr 0
Cash outflow for leases	SFr 530	SFr 390
Bottom of range [member]
Disclosure Of Leases [Line Items]
Lessee lease term of contract	1 year
Top of range [member]
Disclosure Of Leases [Line Items]
Lessee lease term of contract	9 years

Property and equipment - Additi

Property and equipment - Additional Information (Detail) - CHF (SFr) SFr in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure of detailed information about property, plant and equipment [abstract]
Property and equipment	SFr 397	SFr 49

Inventories - Summary of Invent

Inventories - Summary of Inventories (Detail) - CHF (SFr) SFr in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure of Classes of Inventories [Line Items]
Raw material	SFr 2,728	SFr 2,758
Finished goods	656	139
Gross inventories	3,384	2,897
Valuation allowance	(2,827)	(2,670)
Total	SFr 557	SFr 227

Inventories - Additional Inform

Inventories - Additional Information (Detail) SFr in Thousands	Dec. 31, 2023 CHF (SFr)
Inventories [Abstract]
Inventory at acquisition cost	SFr 2,659

Trade receivables - Summary of

Trade receivables - Summary of Current Trade Receivables (Detail) - CHF (SFr) SFr in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure of Detailed Information about Current Trade Receivables [Abstract]
Current receivables	SFr 1,419	SFr 1,548
Expected credit loss allowance	(248)	(227)
Total	SFr 1,171	SFr 1,321

Trade receivables - Summary o_2

Trade receivables - Summary of Trade Receivables Expected Credit Loss Allowance (Detail) - Trade receivables [member] - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of Detailed Information about Trade Receivables Expected Credit Loss Allowance [Line Items]
Balance at beginning of year	SFr (227)	SFr (204)
Impairment losses recognized	(36)	(23)
Reversal of impairment losses	15	0
Balance at end of year	SFr (248)	SFr (227)

Other current assets - Summary

Other current assets - Summary of Information about Other Current Assets (Detail) - CHF (SFr) SFr in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Other Current Assets [Abstract]
Other receivable (note 7.2)	SFr 972	SFr 0
Accrued revenue	501	723
Prepaid expenses	345	836
VAT receivable	168	147
Deposits	9	28
Other current receivables	25	64
Total	SFr 2,020	SFr 1,798

Share capital - Summary of Shar

Share capital - Summary of Share Capital (Detail) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of classes of share capital [line items]
Beginning balance	11,013,813	10,283,668
Direct Share Placement program	24,947	347,145
Private placements	1,200,000
Milestone payments		375,500
Exercise of pre-funded warrants	300,000
Withdrawal of fractional shares	(3,009)
Exercises of options	4,688	7,500
Ending balance	12,540,439	11,013,813
Common shares [member]
Disclosure of classes of share capital [line items]
Beginning balance	14,040,837	11,033,337
Issuance of treasury shares		3,000,000
Exercises of options	0	7,500
Ending balance	14,040,837	14,040,837
Treasury shares [member]
Disclosure of classes of share capital [line items]
Beginning balance	(3,027,024)	(749,669)
Issuance of treasury shares		(3,000,000)
Direct Share Placement program	24,947	347,145
Private placements	1,200,000
Milestone payments		375,500
Exercise of pre-funded warrants	300,000
Withdrawal of fractional shares	(3,009)
Exercises of options	4,688
Ending balance	(1,500,398)	(3,027,024)

Share capital - Additional Info

Share capital - Additional Information (Detail) SFr / shares in Units, SFr in Thousands		12 Months Ended
	Jun. 15, 2023 CHF (SFr) SFr / shares shares	Dec. 31, 2023 CHF (SFr) shares SFr / shares	Dec. 31, 2022 CHF (SFr) shares SFr / shares	Dec. 31, 2023 $ / shares	Jun. 15, 2023 $ / shares shares	May 05, 2023 SFr / shares shares	Dec. 31, 2021 shares
Disclosure of classes of share capital [line items]
Number of shares issued	4,688	12,540,439	11,013,813		4,688		10,283,668
Par value per share | SFr / shares	SFr 3.4	SFr 4
Proceeds from capital increase | SFr	SFr 4,995	SFr 5,014	SFr 60
Equity transaction costs | SFr		SFr 494	SFr 223
Stock issued during period shares treasury stock			3,000,000
Number of instruments granted in share-based payment arrangement		7,500
Acquisition milestone share payments | SFr			SFr 4,200
Shares issued during the period for milestone payments			375,500
Milestone payment per share | SFr / shares			SFr 11.2
Number of shares authorised		2,500,000				0.0025
Conditional share capital | SFr		SFr 16,688
Number of shares reserved for issue under options and contracts for sale of shares		4,171,924
Number of share options outstanding in share-based payment arrangement		126,032	185,908
Share combined into one share						400
Pre reverse split ordinary shares issued						5,616,334,800
Post reverse split ordinary shares issued						14,040,837
Par value of each share multiplied						400
Sale of ordinary share	1,200,000				1,200,000
Pre funded warrants ordinary share purchase	300,000				300,000
Warrants ordinary share purchase	1,500,000				1,500,000
Pre funded par value per share | $ / shares					$ 3.329
Additional amount received on share | SFr	SFr 300
Number of shares issued on direct share placement	24,947				24,947
Average price per share | SFr / shares	SFr 4.07
Gross proceeds direct share placement program | SFr	SFr 102
Par value per share on exercise of option | SFr / shares	SFr 4
Retired of fractional share	3,009				3,009
Fractional share issue cost | SFr	SFr 22
Cash gross proceeds from issuance of shares | SFr		SFr 5,116	SFr 7,111
Private Placement [Member]
Disclosure of classes of share capital [line items]
Number of share options granted in share-based payment arrangement		320,000
Share options [member] | Private Placement [Member]
Disclosure of classes of share capital [line items]
Number of share options outstanding in share-based payment arrangement		126,032
Warrants [member] | Private Placement [Member]
Disclosure of classes of share capital [line items]
Number of share options outstanding in share-based payment arrangement		1,500,000
Bottom of range [member]
Disclosure of classes of share capital [line items]
Par value per share | SFr / shares						SFr 0.01
Top of range [member]
Disclosure of classes of share capital [line items]
Par value per share | SFr / shares						SFr 4
Treasury shares [member]
Disclosure of classes of share capital [line items]
Number of shares issued		(1,500,398)	(3,027,024)				(749,669)
Issuance of treasury shares | SFr			SFr (12,000)
Acquisition milestone share payments | SFr			SFr 1,502
Direct Share Placement Program [member] | Treasury shares [member]
Disclosure of classes of share capital [line items]
Stock issued during period shares treasury stock		347,145
Stock issued during period shares treasury stock, Share price | $ / shares				$ 20.32
Issuance of treasury shares | SFr		SFr 7,051
Share options [member]
Disclosure of classes of share capital [line items]
Proceeds from capital increase | SFr	SFr 19	SFr 60
Share price | $ / shares				$ 8
Number of shares reserved for issue under options and contracts for sale of shares		264,424
Option Rights [member]
Disclosure of classes of share capital [line items]
Number of shares reserved for issue under options and contracts for sale of shares		3,907,500
Ordinary shares [member]
Disclosure of classes of share capital [line items]
Number of shares issued		14,040,837
Par value per share | SFr / shares		SFr 4

Reserves - Summary of Reserves

Reserves - Summary of Reserves (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of reserves within equity [line items]
Other reserves	SFr 220,330	SFr 220,961
Equity [abstract]
Beginning balance	145,417	181,530
Net paid-in capital from capital increases	4,994
Transaction cost in relation to capital increases	(494)	(223)
Share-based payments (note 31)	814	2,186
Exchange differences arising on translating foreign operations	63	461
Ending balance	52,228	145,417
Other reserves [member]
Equity [abstract]
Beginning balance	220,961	210,147
Net paid-in capital from capital increases	194
Transaction cost in relation to capital increases	(494)	(223)
Share-based payments (note 31)	814	2,186
Ending balance	220,330	220,961
Share premium [member]
Disclosure of reserves within equity [line items]
Other reserves	214,180	215,688
Share premium [member] | Other reserves [member]
Equity [abstract]
Beginning balance	215,688	207,521
Net paid-in capital from capital increases	(1,014)	8,390
Transaction cost in relation to capital increases	(494)	(223)
Ending balance	214,180	215,688
Reserve of share-based payments [member]
Disclosure of reserves within equity [line items]
Other reserves	5,371	4,557
Reserve of share-based payments [member] | Other reserves [member]
Equity [abstract]
Beginning balance	4,557	2,371
Share-based payments (note 31)	814	2,186
Ending balance	5,371	4,557
Reserve of exchange differences on translation [member]
Disclosure of reserves within equity [line items]
Other reserves	779	716
Reserve of exchange differences on translation [member] | Other reserves [member]
Equity [abstract]
Beginning balance	716	255
Exchange differences arising on translating foreign operations	63	461
Ending balance	SFr 779	SFr 716

Borrowings - Additional Informa

Borrowings - Additional Information (Detail) SFr in Thousands	12 Months Ended
	Dec. 31, 2023 CHF (SFr)
Bank loan One [member]
Disclosure of detailed information about borrowings [line items]
Notional amount	SFr 331
Borrowings, interest rate	2.70%
Borrowings, maturity	January 31, 2024
Bank loan Two [member]
Disclosure of detailed information about borrowings [line items]
Notional amount	SFr 15
Borrowings, maturity	2026

Defined benefit obligations - S

Defined benefit obligations - Summary of Defined Benefit Plans (Detail) - CHF (SFr) SFr in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure of information about defined benefit plans [abstract]
Present value of pension benefit obligation	SFr 4,517	SFr 4,044
Fair value of pension plan assets	(3,532)	(3,494)
Net pension defined benefit obligation	985	550
Present value of other benefit obligations	604	1,222
Total defined benefit obligations	SFr 1,589	SFr 1,772

Defined benefit obligations -_2

Defined benefit obligations - Summary of Amount Recognized In Profit Or Loss In Respect of Defined Benefit Plans (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of information about defined benefit plans [abstract]
Net service cost	SFr 212	SFr 207
Net interest expense	7	4
Administration cost excl. cost for managing plan assets	31	23
Expense recognized in profit or loss	SFr 250	SFr 234

Defined benefit obligations -_3

Defined benefit obligations - Summary of Amount Recognized In Other Comprehensive Income In Respect of Defined Benefit Plans (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of information about defined benefit plans [abstract]
due to changes in demographic assumptions	SFr (11)	SFr 0
due to changes in financial assumptions	426	(1,150)
due to changes in experience adjustments	(31)	156
Return on plan assets excl. interest income	100	52
Expense/(Income) recognized in other comprehensive income	SFr 484	SFr (942)

Defined benefit obligations -_4

Defined benefit obligations - Summary of Movement In The Present Value of Defined Benefit Obligation (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of net defined benefit liability (asset) [line items]
Remeasurement (gain)/loss due to changes in demographic assumptions	SFr 11	SFr 0
Present value of defined benefit obligation [member]
Disclosure of net defined benefit liability (asset) [line items]
Opening Balance	4,044	4,496
Net service cost	212	207
Interest expense on defined benefit obligation	85	13
Contributions from plan participants	129	129
Benefits (paid)/deposited	(337)	193
Remeasurement (gain)/loss due to changes in demographic assumptions	(11)	0
Remeasurement (gain)/loss due to changes in financial assumptions	426	(1,150)
Remeasurement (gain)/loss due to changes in experience adjustments	(31)	156
Closing Balance	SFr 4,517	SFr 4,044

Defined benefit obligations -_5

Defined benefit obligations - Summary of Movement In The Present Value of Defined Benefit Plan Assets (Detail) - Plan assets [member] - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of net defined benefit liability (asset) [line items]
Opening Balance	SFr 3,494	SFr 2,946
Interest income on plan assets	78	9
Return on plan assets excluding interest income	(100)	(52)
Contributions from the employer	299	292
Contributions from plan participants	129	129
Benefits (paid)/deposited	(337)	193
Administration cost	(31)	(23)
Closing Balance	SFr 3,532	SFr 3,494

Defined benefit obligations -_6

Defined benefit obligations - Summary of Detailed Information About Principal Actuarial Assumptions (Detail)	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Detailed Information About Principal Actuarial Assumptions [Abstract]
Discount rate	1.40%	2.15%
Expected rate of salary increase	1.90%	1.50%

Defined benefit obligations - A

Defined benefit obligations - Additional Information (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of defined benefit plans [line items]
Actual return on plan assets	SFr 22	SFr 43
Weighted average duration of defined benefit obligation	15 years 2 months 12 days	14 years 4 months 24 days
Pension defined benefit plans [member]
Disclosure of defined benefit plans [line items]
Employer contributions	SFr 289
Actuarial assumption of discount rates [member]
Disclosure of defined benefit plans [line items]
Percentage of reasonably possible increase in actuarial assumption	25%
Percentage of reasonably possible decrease in actuarial assumption	25%
Percentage of decrease in defined benefit obligation due to reasonably possible increase in actuarial assumption	3.70%
Percentage of Increase in defined benefit obligation due to reasonably possible Decrease in actuarial assumption	3.90%
Actuarial assumption of expected rates of salary increases [member]
Disclosure of defined benefit plans [line items]
Percentage of reasonably possible increase in actuarial assumption	0.25%
Percentage of reasonably possible decrease in actuarial assumption	0.25%
Percentage of decrease in defined benefit obligation due to reasonably possible increase in actuarial assumption	0.60%
Percentage of Increase in defined benefit obligation due to reasonably possible Decrease in actuarial assumption	0.60%

Provisions - Summary of Provis

Provisions - Summary of Provisions (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Provisions [Line Items]
Beginning balance	SFr 11,003
Addition	235
Unwinding of discount on provisions	303	SFr 1,308
Variation due to assumption adjustment	(4,782)
Foreign exchange difference	(185)
Utilization	(136)
Ending balance	6,438	11,003
thereof current	235	3,094
thereof non-current	6,203	7,909
Contingent liabilities [member]
Disclosure Of Provisions [Line Items]
Beginning balance	10,867
Unwinding of discount on provisions	303
Variation due to assumption adjustment	(4,782)
Foreign exchange difference	(185)
Ending balance	6,203	10,867
thereof non-current	6,203
Legal and regulatory [member]
Disclosure Of Provisions [Line Items]
Beginning balance	136
Utilization	(136)
Ending balance		SFr 136
Other [Member]
Disclosure Of Provisions [Line Items]
Addition	235
Ending balance	235
thereof current	SFr 235

Provisions - Additional Informa

Provisions - Additional Information (Detail) SFr in Thousands, € in Millions	12 Months Ended
	Dec. 31, 2023 CHF (SFr)	Dec. 31, 2023 EUR (€)	Dec. 31, 2022 CHF (SFr)
Disclosure Of Provisions [Line Items]
Provisions	SFr 6,438		SFr 11,003
Discount rate on provision	5%
Consideration transferred, acquisition-date fair value	SFr 4,782
Legal proceedings provision	136
Actual Legal Proceedings Provision	142
Termination benefits expense	SFr 235
Bottom of range [member]
Disclosure Of Provisions [Line Items]
Percentage weighted present value of potential payments	12%
Top of range [member]
Disclosure Of Provisions [Line Items]
Percentage weighted present value of potential payments	75%
AdVita [member]
Disclosure Of Provisions [Line Items]
Contingent payments	SFr 9,300	€ 10
APR [member]
Disclosure Of Provisions [Line Items]
Contingent payments	28,000
Contingent liabilities [member]
Disclosure Of Provisions [Line Items]
Provisions	SFr 6,203		SFr 10,867

Financial liabilities due to _2

Financial liabilities due to related parties - Additional Information (Detail) - Share Subscription Facility [member] - GEM Global Yield LLC [member] - CHF (SFr) SFr in Thousands	1 Months Ended
	Jan. 31, 2021	Dec. 31, 2023	Dec. 31, 2022
Disclosure of Financial Liabilities Due to Related Parties [Line Items]
Credit facility maximum borrowing capacity	SFr 50,000
Borrowings, maturity	January 20, 2024
Borrowings		SFr 0
Commitment fee payable			SFr 1,250
Borrowings, adjustment to interest rate basis			1%
Commitment period	3 years

Other current payables and li_3

Other current payables and liabilities - Summary of Current Payables and Liabilities (Detail) - CHF (SFr) SFr in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure of other current payables and liabilities [Abstract]
Accrued expenses	SFr 1,736	SFr 2,138
Personnel-related accruals and payables	1,049	497
Stamp duty and capital tax liabilities	51	347
Deferred revenue	114	776
Other current liabilities	483	143
Total	SFr 3,433	SFr 3,901

Other gains - Summary of Other

Other gains - Summary of Other Gains (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Expenses by nature [abstract]
Divestment gain	SFr 125	SFr 0
Income from sublease agreements	99	94
Reversal of impairment on financial assets	0	453
Reversal of impairment on other receivables	58	235
Various other	13	247
Total other gains	SFr 295	SFr 1,029

Personnel expenses - Summary of

Personnel expenses - Summary of Information About Employee Benefit Expenses (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Classes of employee benefits expense [abstract]
Salaries and social security expense	SFr 11,088	SFr 10,513
Independent contractors fees	0	320
Share-based payment expense	814	2,186
Service cost for other benefit obligations	(64)	(21)
Total personnel expenses	SFr 11,838	SFr 12,998

Other administrative expenses -

Other administrative expenses - Summary of Information About Other Administrative Expenses (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Administrative Expenses [Abstract]
Professional services	SFr 2,918	SFr 6,053
Other administrative expenses	2,473	1,694
Total other administrative expenses	SFr 5,391	SFr 7,747

Impairment expense - Summary of

Impairment expense - Summary of Impairment Expense (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Impairment Expenses [Abstract]
Impairment losses on intangible assets	SFr 95,895	SFr 26,424
Impairment losses on inventories	184	0
Total impairment expense	SFr 96,079	SFr 26,424

Amortization and depreciation_3

Amortization and depreciation expense - Summary of Amortization and Depreciation Expenses (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Depreciation and amortisation expense [abstract]
Amortization of intangible assets (note 7)	SFr 2,682	SFr 3,448
Depreciation of rights-of-use assets (note 8)	537	392
Depreciation of property and equipment (note 9)	99	20
Total amortization and depreciation expense	SFr 3,318	SFr 3,860

Financial income and expenses -

Financial income and expenses - Summary of Financial Income and Expenses (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
DisclosureOfFinanceIncomeExpense [Abstract]
Interest income on cash deposits	SFr 64	SFr 0
Interest income on deferred payment	29	0
Interest income on loans	0	18
Total financial income	93	18
Unwinding of discount on provisions	(303)	(1,308)
SSF commitment fee	(417)	(416)
Negative interest on cash deposits	0	(93)
Interest expense related to leases	(27)	(33)
Bank charges	(20)	(40)
Foreign exchange loss, net	(65)	(374)
Other interest expenses	(117)	(30)
Total financial expenses	SFr (949)	SFr (2,294)

Income Taxes - Summary of Incom

Income Taxes - Summary of Income Tax Recognized In Profit or Loss (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Current tax
Current tax expense for the year	SFr 0	SFr 0
Adjustments in current tax of prior years	0	0
Current tax	0	0
Deferred tax
Deferred tax income for the year	(13,503)	(4,977)
Write-down of deferred tax assets	0	1,451
Deferred tax	(13,503)	(3,526)
Net income tax gain	SFr (13,503)	SFr (3,526)

Income Taxes - Summary of Detai

Income Taxes - Summary of Detailed Information About Reconciliation of Effective and Applicable Income Tax Expenses (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Income Tax [Abstract]
Loss before tax	SFr (111,684)	SFr (54,316)
Income tax expense calculated at 13.99% (2022: 13.99%)	(15,625)	(7,599)
Unrecognized deferred tax assets during the year	2,138	4,235
Write-down of deferred tax assets	0	1,451
Effect of deferred tax balances due to difference in applicable tax rates	24	(802)
Effect of net (income)/expense that is not added/(deductible)	(40)	(811)
Net income tax gain	SFr (13,503)	SFr (3,526)

Income Taxes - Summary of Det_2

Income Taxes - Summary of Detailed Information About Reconciliation of Effective and Applicable Income Tax Expenses (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Income Tax [Abstract]
Applicable tax rate	13.99%	13.99%

Income Taxes - Summary of Tempo

Income Taxes - Summary of Temporary Difference, Unused Tax Losses And Unused Tax Credits (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Recognized in OCI	SFr 0	SFr 0
Recognized in profit or loss	(13,503)	(4,977)
Opening balance	495	1,737
Recognized in OCI	0	0
Recognized in profit or loss	94	(1,242)
Closing balance	589	495
Opening balance	20,736	25,504
Recognized in profit or loss		(4,768)
Closing balance		20,736
Opening balance	20,736	25,504
Recognized in profit or loss	(13,370)	(4,768)
Closing balance	7,366	20,736
Tax losses [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Opening balance	495	1,206
Recognized in OCI	0	0
Recognized in profit or loss	94	(711)
Closing balance	589	495
Opening balance	22,000
Closing balance	24,000	22,000
Defined benefit obligation [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Opening balance	0	247
Recognized in OCI		0
Recognized in profit or loss		(247)
Closing balance		0
Intangible assets [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Opening balance	0	280
Recognized in OCI		0
Recognized in profit or loss		(280)
Closing balance		0
Opening balance	20,736
Recognized in profit or loss	(13,370)
Closing balance	7,366	20,736
Leases [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Opening balance	SFr 0	4
Recognized in OCI		0
Recognized in profit or loss		(4)
Closing balance		SFr 0

Income Taxes - Summary of Det_3

Income Taxes - Summary of Detailed Information About Unrecognized Deferred Tax Assets (Detail) - CHF (SFr) SFr in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Income Tax [line Items]
Unused tax losses for which no deferred tax asset recognised	SFr 155,788	SFr 144,858
Within one year [member]
Disclosure Of Income Tax [line Items]
Unused tax losses for which no deferred tax asset recognised	2,951	7,833
Later than one year and not later than five years [member]
Disclosure Of Income Tax [line Items]
Unused tax losses for which no deferred tax asset recognised	102,014	70,009
More than five years [member]
Disclosure Of Income Tax [line Items]
Unused tax losses for which no deferred tax asset recognised	SFr 50,823	SFr 67,016

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Applicable tax rate	13.99%	13.99%
Income tax relating to components of other comprehensive income	SFr 0	SFr 0
Deferred tax assets	589	495	SFr 1,737
Income taxes	13,503	3,526
Tax losses [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Income tax relating to components of other comprehensive income	0	0
Deferred tax assets	SFr 24,000	SFr 22,000

Share-based payments - Summary

Share-based payments - Summary of Stock Options Outstanding (Detail)	12 Months Ended
	Dec. 31, 2023 shares $ / shares	Dec. 31, 2022 shares $ / shares
Disclosure Of Number And Weighted Average Exercise Price Of Share Options [line Items]
At beginning of the year	185,908
At end of the year	126,032	185,908
Two Thousand And Twenty One Stock Option Programme And Equity Award Programme Two Thousand And Fifteen [member]
Disclosure Of Number And Weighted Average Exercise Price Of Share Options [line Items]
At beginning of the year	185,908	171,627
Granted	20,184	30,250
Exercised	(4,871)	(7,500)
Forfeited	(75,189)	(8,469)
At end of the year	126,032	185,908
Weighted average exercise price of granted options, in CHF | $ / shares	$ 8.21	$ 16.04
Weighted average exercise price of exercised options, in CHF | $ / shares	4	8
Weighted average exercise price of outstanding options, in CHF | $ / shares	$ 22.43	$ 22.98

Share-based payments - Summar_2

Share-based payments - Summary of Share Options Outstanding (Detail) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share based compensation by share based award options outstanding	126,032	185,908
Exercisable	92,866	69,541
Weighted average remaining contractual life, in months	43 months	69 months
Two Thousand And Twenty One Stock Option Programme And Equity Award Programme Two Thousand And Fifteen [member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share based compensation by share based award options outstanding	126,032	185,908	171,627
Two Thousand And Twenty One Stock Option Programme And Equity Award Programme Two Thousand And Fifteen [member] | 2023 [member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share based compensation by share based award options outstanding	0	250
Two Thousand And Twenty One Stock Option Programme And Equity Award Programme Two Thousand And Fifteen [member] | 2024 [member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share based compensation by share based award options outstanding	26,374	250
Two Thousand And Twenty One Stock Option Programme And Equity Award Programme Two Thousand And Fifteen [member] | 2025 [member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share based compensation by share based award options outstanding	250	250
Two Thousand And Twenty One Stock Option Programme And Equity Award Programme Two Thousand And Fifteen [member] | 2026 [member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share based compensation by share based award options outstanding	18,491	18,491
Two Thousand And Twenty One Stock Option Programme And Equity Award Programme Two Thousand And Fifteen [member] | 2027 [member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share based compensation by share based award options outstanding	24,084	53,917
Two Thousand And Twenty One Stock Option Programme And Equity Award Programme Two Thousand And Fifteen [member] | 2028 [member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share based compensation by share based award options outstanding	28,333	55,667
Two Thousand And Twenty One Stock Option Programme And Equity Award Programme Two Thousand And Fifteen [member] | 2029 [member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share based compensation by share based award options outstanding	24,250	47,833
Two Thousand And Twenty One Stock Option Programme And Equity Award Programme Two Thousand And Fifteen [member] | 2030 [member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share based compensation by share based award options outstanding	4,250	9,250

Share-based payments - Summar_3

Share-based payments - Summary of Share Options Outstanding Exercise Prices (Detail) - shares	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price	126,032	185,908
Two Thousand And Twenty One Stock Option Programme And Equity Award Programme Two Thousand And Fifteen [Member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price	126,032	185,908	171,627
Two Thousand And Twenty One Stock Option Programme And Equity Award Programme Two Thousand And Fifteen [Member] | Exercise Price1 [Member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price	56,158	63,658
Two Thousand And Twenty One Stock Option Programme And Equity Award Programme Two Thousand And Fifteen [Member] | Exercise Price 2 [Member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price	7,500	37,500
Two Thousand And Twenty One Stock Option Programme And Equity Award Programme Two Thousand And Fifteen [Member] | Exercise Price 3 [Member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price	16,292	35,250
Two Thousand And Twenty One Stock Option Programme And Equity Award Programme Two Thousand And Fifteen [Member] | Exercise Price 4 [Member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price	46,082	49,500

Share-based payments - Summar_4

Share-based payments - Summary of Share Options Outstanding Exercise Prices (parenthetical) (Detail) - Two Thousand And Twenty One Stock Option Programme And Equity Award Programme Two Thousand And Fifteen [Member]	Dec. 31, 2023 $ / shares
Exercise Price 4 [Member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price of outstanding share options	$ 20
Bottom of range [member] | Exercise Price1 [Member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price of outstanding share options	4
Bottom of range [member] | Exercise Price 2 [Member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price of outstanding share options	5.01
Bottom of range [member] | Exercise Price 3 [Member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price of outstanding share options	10.01
Top of range [member] | Exercise Price1 [Member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price of outstanding share options	5
Top of range [member] | Exercise Price 2 [Member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price of outstanding share options	10
Top of range [member] | Exercise Price 3 [Member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price of outstanding share options	$ 20

Share-based payments - Addition

Share-based payments - Additional Information (Detail) SFr / shares in Units, SFr in Thousands	12 Months Ended
	Dec. 31, 2023 shares $ / shares	Dec. 31, 2023 CHF (SFr) shares SFr / shares	Dec. 31, 2022 CHF (SFr) shares SFr / shares	Dec. 31, 2021 shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share based compensation by share based award options outstanding | shares	126,032	126,032	185,908
Two Thousand And Twenty One Stock Option Programme And Equity Award Programme Two Thousand And Fifteen [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share based compensation by share based award options outstanding | shares	126,032	126,032	185,908	171,627
Weighted average fair value per share option granted		SFr 1.04	SFr 8
Number of share options granted | shares	320,000	320,000
Weighted average share price | $ / shares	$ 2
Number of share options forfeited in share-based payment arrangement | shares		75,189	8,469
Two Thousand And Twenty One Stock Option Programme And Equity Award Programme Two Thousand And Fifteen [member] | Personnel Expenses [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Allocated share based compensation | SFr		SFr 814	SFr 2,186
Two Thousand And Twenty One Stock Option Programme And Equity Award Programme Two Thousand And Fifteen [member] | Top of range [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average share price, share options granted		SFr 9.2	SFr 24
Exercise price of share options granted		SFr 9.2	SFr 24
Expected volatility share options granted		69%	80%
Risk free interest rate share options granted		1.23%	1%
Two Thousand And Twenty One Stock Option Programme And Equity Award Programme Two Thousand And Fifteen [member] | Bottom of range [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average share price, share options granted		SFr 1.87	SFr 10.8
Exercise price of share options granted		SFr 2	SFr 10.8
Expected volatility share options granted		66%	71%
Risk free interest rate share options granted		1.06%	0%

Earnings per share - Summary of

Earnings per share - Summary of Earnings Per Share (Detail) - CHF (SFr) SFr / shares in Units, SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Earnings per share [abstract]
Loss attributable to shareholders (in TCHF)	SFr (98,181)	SFr (50,790)
Weighted average number of shares - basic	11,752,466	10,570,281
Weighted average number of shares - diluted	11,752,466	10,570,281
Total basic and diluted loss per share (in CHF) - basic	SFr (8.354)	SFr (4.805)
Total basic and diluted loss per share (in CHF) - diluted	SFr (8.354)	SFr (4.805)

Financial Instruments - Summary

Financial Instruments - Summary of Categories of Financial Instruments (Detail) - CHF (SFr) SFr in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure of detailed information about financial instruments [line items]
Financial assets at amortized cost	SFr 17,583	SFr 21,628
Financial liabilities at amortized cost	7,556	8,183
Financial liabilities at FVTPL	6,203	10,867
Financial assets	17,583	21,628
Financial liabilities	13,759	19,050
Non Current Lease Liabilities [member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities at amortized cost	2,086	2,232
Financial liabilities	2,086	2,232
Non Current Borrowings [member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities at amortized cost	9	16
Financial liabilities	9	16
Current Lease Liabilities [member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities at amortized cost	524	444
Financial liabilities	524	444
Current Borrowings [member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities at amortized cost	337	372
Financial liabilities	337	372
Provisions For Milestone Payments [member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities at amortized cost	0	0
Financial liabilities at FVTPL	6,203	10,867
Financial liabilities	6,203	10,867
Trade Payables [member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities at amortized cost	1,025	1,625
Financial liabilities	1,025	1,625
Financial Liabilities Due To Related Parties [member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities at amortized cost	1,355	1,280
Financial liabilities	1,355	1,280
Other Current Payables And Liabilities [member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities at amortized cost	2,220	2,214
Financial liabilities	2,220	2,214
Other Non Current Assets [member]
Disclosure of detailed information about financial instruments [line items]
Financial assets at amortized cost	116	114
Financial assets	116	114
Trade receivables [member]
Disclosure of detailed information about financial instruments [line items]
Financial assets at amortized cost	1,171	1,321
Financial assets	1,171	1,321
Other Current Assets And Receivables [member]
Disclosure of detailed information about financial instruments [line items]
Financial assets at amortized cost	1,740	956
Financial assets	1,740	956
Cash And Cash Equivalents [member]
Disclosure of detailed information about financial instruments [line items]
Financial assets at amortized cost	14,556	19,237
Financial assets	SFr 14,556	SFr 19,237

Financial Instruments - Summa_2

Financial Instruments - Summary of Reconciliation of Liabilities Arising From Financing Activities (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Opening balance	SFr 4,344	SFr 4,264
Financing cash flows	(550)	(471)
Additional leases	420	551
Accrued interest	75	31
Foreign exchange	22	(31)
Closing balance	4,311	4,344
Lease liabilities [member]
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Opening balance	2,676	2,523
Financing cash flows	(530)	(390)
Additional leases	420	551
Accrued interest	0	0
Foreign exchange	44	(8)
Closing balance	2,610	2,676
Long-term borrowings [member]
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Opening balance	388	491
Financing cash flows	(20)	(81)
Additional leases	0	0
Accrued interest	0	1
Foreign exchange	(22)	(23)
Closing balance	346	388
Due To Related Parties [member]
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Opening balance	1,280	1,250
Financing cash flows	0	0
Additional leases	0	0
Accrued interest	75	30
Foreign exchange	0	0
Closing balance	SFr 1,355	SFr 1,280

Financial risk management - Add

Financial risk management - Additional Information (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
United States of America, Dollars
Disclosure Of Financial Risk Management [Line Items]
Percentage of reasonably possible increase in unobservable input assets	5%
Percentage of reasonably possible decrease in unobservable input assets	5%
Increase decrease in fair value measurement due to reasonably possible increase in unobservable input recognized in profit or loss before tax assets	SFr 384	SFr 251
Increase decrease in fair value measurement due to reasonably possible decrease in unobservable input recognized in profit or loss before tax assets	SFr 384	251
Euro Member Countries, Euro
Disclosure Of Financial Risk Management [Line Items]
Percentage of reasonably possible increase in unobservable input assets	5%
Percentage of reasonably possible decrease in unobservable input assets	5%
Increase decrease in fair value measurement due to reasonably possible increase in unobservable input recognized in profit or loss before tax assets	SFr 384	251
Increase decrease in fair value measurement due to reasonably possible decrease in unobservable input recognized in profit or loss before tax assets	SFr 384	SFr 251

Related party transactions - Su

Related party transactions - Summary of With Members of the Board of Directors and of the Executive Committee (Detail) - CHF (SFr) SFr in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of transactions between related parties [abstract]
Short-term employee benefits	SFr 2,267	SFr 2,873
Post-employment benefits	90	89
Other benefits	452	0
Share-based compensation	246	0
Total compensation	SFr 3,055	SFr 2,962

Related party transactions - Ad

Related party transactions - Additional Information (Detail) - CHF (SFr) SFr in Thousands	Dec. 31, 2023	Dec. 31, 2022
Gem [member]
Disclosure of transactions between related parties [line items]
Non current financial liabilities at amortized cost	SFr 1,355	SFr 1,280

Non-cash transactions - Additio

Non-cash transactions - Additional Information (Detail) SFr in Thousands	12 Months Ended
	Dec. 31, 2022 CHF (SFr)
Disclosure In Entirety Of Non Cash Transactions [Line Items]
Share based compensation by share based award value issued towards milestone payment	SFr 4,200

Contingent liabilities - Additi

Contingent liabilities - Additional Information (Detail) SFr in Thousands, € in Millions, $ in Millions	1 Months Ended
	Aug. 31, 2023	Dec. 31, 2023 CHF (SFr)	Dec. 31, 2023 EUR (€)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 CHF (SFr)
APR [member]
Disclosure of contingent liabilities [line items]
Business combination contingent consideration payable		SFr 28,000
AdVita [member]
Disclosure of contingent liabilities [line items]
Business combination contingent consideration payable		9,300	€ 10
Apr And Advita [member]
Disclosure of contingent liabilities [line items]
Current provision		6,200			SFr 10,900
Meta Health Care Limited [member]
Disclosure of contingent liabilities [line items]
Additional contingent milestone payment payable		250
Acer [member]
Disclosure of contingent liabilities [line items]
Percentage of royalties on estimated future net revenues	10%
Percentage of relief from sublicensing transaction	20%
Neuro Rx Pharmaceuticals [member] | Based On Marketing Approval [member] | Settlement Agreement [member]
Disclosure of contingent liabilities [line items]
Milestone payment payable		10,900		$ 13
Neuro Rx Pharmaceuticals [member] | Based On Future Sales [member] | Settlement Agreement [member]
Disclosure of contingent liabilities [line items]
Milestone payment payable		SFr 25,200		$ 30

Events After The Reporting Pe_2

Events After The Reporting Period - Additional Information (Detail) SFr / shares in Units, SFr in Thousands, $ in Millions		1 Months Ended
	Apr. 26, 2024 SFr / shares shares	Feb. 29, 2024 CHF (SFr) SFr / shares	Mar. 21, 2024 CHF (SFr)	Mar. 21, 2024 USD ($)	Dec. 31, 2023 SFr / shares	Jun. 15, 2023 SFr / shares
Disclosure of non-adjusting events after reporting period [line items]
Par value per share					SFr 4	SFr 3.4
Ordinary shares [member]
Disclosure of non-adjusting events after reporting period [line items]
Par value per share					SFr 4
Upfront Payments [member] | Eton Pharmaceuticals Inc [member] | License and Supply Agreement [member] | Based On Marketing Approval [member]
Disclosure of non-adjusting events after reporting period [line items]
Milestone payment received			SFr 2,000	$ 2.2
Exclusive Right Of Royalties [member] | Eton Pharmaceuticals Inc [member] | License and Supply Agreement [member] | Based On Future Sales [member]
Disclosure of non-adjusting events after reporting period [line items]
Maximum eligible of milestone payment received			SFr 1,800	$ 2
Subsequent changes to the capital structure [member] | Ordinary shares [member]
Disclosure of non-adjusting events after reporting period [line items]
Par value per share before reduction	SFr 4
Par value per share after reduction	SFr 0.1
Subsequent changes to the capital structure [member] | Capital Band [member]
Disclosure of non-adjusting events after reporting period [line items]
Increase (decrease) in number of shares outstanding | shares	7,000,000
Subsequent changes to the capital structure [member] | Conditional Capital [member]
Disclosure of non-adjusting events after reporting period [line items]
Increase (decrease) in number of shares outstanding | shares	7,000,000
Share Subscription Facility [member] | SSF agreement with GEM Renewed [member]
Disclosure of non-adjusting events after reporting period [line items]
Term of warrants		3 years
Outstanding liability forgive by gem | SFr		SFr 1,368
Warrants issued | SFr		SFr 3,350
Expired date of warrants		Jan. 20, 2027
Share Subscription Facility [member] | SSF agreement with GEM Renewed [member] | Warrants [member]
Disclosure of non-adjusting events after reporting period [line items]
Par value per share		SFr 1.7